KR102076932B1 - Composition for skin whitening comprising octadecene or its salt as active ingredients - Google Patents
Composition for skin whitening comprising octadecene or its salt as active ingredients Download PDFInfo
- Publication number
- KR102076932B1 KR102076932B1 KR1020190071588A KR20190071588A KR102076932B1 KR 102076932 B1 KR102076932 B1 KR 102076932B1 KR 1020190071588 A KR1020190071588 A KR 1020190071588A KR 20190071588 A KR20190071588 A KR 20190071588A KR 102076932 B1 KR102076932 B1 KR 102076932B1
- Authority
- KR
- South Korea
- Prior art keywords
- octadecene
- composition
- skin
- present
- acid
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims abstract description 108
- CCCMONHAUSKTEQ-UHFFFAOYSA-N octadecene Natural products CCCCCCCCCCCCCCCCC=C CCCMONHAUSKTEQ-UHFFFAOYSA-N 0.000 title claims abstract description 94
- 150000003839 salts Chemical class 0.000 title claims abstract description 61
- 239000004480 active ingredient Substances 0.000 title claims abstract description 43
- 230000002087 whitening effect Effects 0.000 title claims abstract description 27
- 239000002537 cosmetic Substances 0.000 claims abstract description 31
- WHNFPRLDDSXQCL-UAZQEYIDSA-N α-msh Chemical compound C([C@@H](C(=O)N[C@@H](CO)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC=1NC=NC=1)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)NCC(=O)N[C@@H](CCCCN)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](C(C)C)C(N)=O)NC(=O)[C@H](CO)NC(C)=O)C1=CC=C(O)C=C1 WHNFPRLDDSXQCL-UAZQEYIDSA-N 0.000 claims abstract description 22
- 239000003814 drug Substances 0.000 claims abstract description 20
- XUMBMVFBXHLACL-UHFFFAOYSA-N Melanin Chemical compound O=C1C(=O)C(C2=CNC3=C(C(C(=O)C4=C32)=O)C)=C2C4=CNC2=C1C XUMBMVFBXHLACL-UHFFFAOYSA-N 0.000 claims abstract description 18
- 229940079593 drug Drugs 0.000 claims abstract description 16
- 238000004519 manufacturing process Methods 0.000 claims abstract description 16
- 239000000637 Melanocyte-Stimulating Hormone Substances 0.000 claims abstract description 7
- 108010007013 Melanocyte-Stimulating Hormones Proteins 0.000 claims abstract description 7
- 102400000740 Melanocyte-stimulating hormone alpha Human genes 0.000 claims description 16
- 101710200814 Melanotropin alpha Proteins 0.000 claims description 16
- 208000012641 Pigmentation disease Diseases 0.000 claims description 16
- 108060008724 Tyrosinase Proteins 0.000 claims description 13
- 102000003425 Tyrosinase Human genes 0.000 claims description 12
- 230000014509 gene expression Effects 0.000 claims description 11
- 230000002265 prevention Effects 0.000 claims description 11
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 108091023040 Transcription factor Proteins 0.000 claims description 7
- 102000040945 Transcription factor Human genes 0.000 claims description 7
- 230000006872 improvement Effects 0.000 claims description 7
- 238000000034 method Methods 0.000 claims description 7
- 208000009795 Microphthalmos Diseases 0.000 claims description 5
- 201000010478 microphthalmia Diseases 0.000 claims description 5
- 238000007911 parenteral administration Methods 0.000 claims description 4
- 230000008099 melanin synthesis Effects 0.000 abstract description 16
- 230000000694 effects Effects 0.000 abstract description 14
- 230000002401 inhibitory effect Effects 0.000 abstract description 12
- 239000000463 material Substances 0.000 abstract description 4
- 235000013402 health food Nutrition 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 46
- 238000002360 preparation method Methods 0.000 description 38
- 210000004027 cell Anatomy 0.000 description 24
- 239000006210 lotion Substances 0.000 description 24
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 22
- 210000002752 melanocyte Anatomy 0.000 description 22
- -1 body cleanser Substances 0.000 description 21
- 239000006071 cream Substances 0.000 description 21
- 238000009472 formulation Methods 0.000 description 20
- 230000036541 health Effects 0.000 description 19
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 18
- 235000013376 functional food Nutrition 0.000 description 16
- 239000002253 acid Substances 0.000 description 15
- PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 14
- 239000004615 ingredient Substances 0.000 description 13
- 235000013305 food Nutrition 0.000 description 11
- 150000001875 compounds Chemical class 0.000 description 10
- 239000000843 powder Substances 0.000 description 10
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 9
- 239000000796 flavoring agent Substances 0.000 description 9
- 239000008187 granular material Substances 0.000 description 9
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 9
- 239000002775 capsule Substances 0.000 description 8
- 239000008188 pellet Substances 0.000 description 8
- 239000003826 tablet Substances 0.000 description 8
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 7
- 235000013361 beverage Nutrition 0.000 description 7
- 235000011187 glycerol Nutrition 0.000 description 7
- 235000016709 nutrition Nutrition 0.000 description 7
- 239000000546 pharmaceutical excipient Substances 0.000 description 7
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 6
- 108020004414 DNA Proteins 0.000 description 6
- KWYUFKZDYYNOTN-UHFFFAOYSA-M Potassium hydroxide Chemical compound [OH-].[K+] KWYUFKZDYYNOTN-UHFFFAOYSA-M 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- 239000000839 emulsion Substances 0.000 description 6
- 235000019634 flavors Nutrition 0.000 description 6
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
- 230000003061 melanogenesis Effects 0.000 description 6
- 239000000049 pigment Substances 0.000 description 6
- 229940088594 vitamin Drugs 0.000 description 6
- 229930003231 vitamin Natural products 0.000 description 6
- 235000013343 vitamin Nutrition 0.000 description 6
- 239000011782 vitamin Substances 0.000 description 6
- 230000008859 change Effects 0.000 description 5
- 239000000686 essence Substances 0.000 description 5
- 239000000284 extract Substances 0.000 description 5
- 239000007788 liquid Substances 0.000 description 5
- 230000035764 nutrition Effects 0.000 description 5
- 239000002674 ointment Substances 0.000 description 5
- 239000000243 solution Substances 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 4
- 229920003171 Poly (ethylene oxide) Polymers 0.000 description 4
- CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 4
- 229930006000 Sucrose Natural products 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 235000015872 dietary supplement Nutrition 0.000 description 4
- 239000003085 diluting agent Substances 0.000 description 4
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 4
- 239000003921 oil Substances 0.000 description 4
- 235000019198 oils Nutrition 0.000 description 4
- 239000000047 product Substances 0.000 description 4
- 239000002994 raw material Substances 0.000 description 4
- 239000011734 sodium Substances 0.000 description 4
- 229910052708 sodium Inorganic materials 0.000 description 4
- 239000007787 solid Substances 0.000 description 4
- 239000005720 sucrose Substances 0.000 description 4
- 239000004094 surface-active agent Substances 0.000 description 4
- 239000000725 suspension Substances 0.000 description 4
- PUPZLCDOIYMWBV-UHFFFAOYSA-N (+/-)-1,3-Butanediol Chemical compound CC(O)CCO PUPZLCDOIYMWBV-UHFFFAOYSA-N 0.000 description 3
- VBICKXHEKHSIBG-UHFFFAOYSA-N 1-monostearoylglycerol Chemical compound CCCCCCCCCCCCCCCCCC(=O)OCC(O)CO VBICKXHEKHSIBG-UHFFFAOYSA-N 0.000 description 3
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 3
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 3
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 3
- IVOMOUWHDPKRLL-KQYNXXCUSA-N Cyclic adenosine monophosphate Chemical compound C([C@H]1O2)OP(O)(=O)O[C@H]1[C@@H](O)[C@@H]2N1C(N=CN=C2N)=C2N=C1 IVOMOUWHDPKRLL-KQYNXXCUSA-N 0.000 description 3
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
- FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- IAJILQKETJEXLJ-UHFFFAOYSA-N Galacturonsaeure Natural products O=CC(O)C(O)C(O)C(O)C(O)=O IAJILQKETJEXLJ-UHFFFAOYSA-N 0.000 description 3
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 3
- GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 3
- 101800001751 Melanocyte-stimulating hormone alpha Proteins 0.000 description 3
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 3
- MUBZPKHOEPUJKR-UHFFFAOYSA-N Oxalic acid Chemical compound OC(=O)C(O)=O MUBZPKHOEPUJKR-UHFFFAOYSA-N 0.000 description 3
- 102100027467 Pro-opiomelanocortin Human genes 0.000 description 3
- 229920002472 Starch Polymers 0.000 description 3
- 244000299461 Theobroma cacao Species 0.000 description 3
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 3
- TVXBFESIOXBWNM-UHFFFAOYSA-N Xylitol Natural products OCCC(O)C(O)C(O)CCO TVXBFESIOXBWNM-UHFFFAOYSA-N 0.000 description 3
- 230000009471 action Effects 0.000 description 3
- 239000002585 base Substances 0.000 description 3
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 3
- 150000001720 carbohydrates Chemical class 0.000 description 3
- 235000014633 carbohydrates Nutrition 0.000 description 3
- 239000000969 carrier Substances 0.000 description 3
- 239000004359 castor oil Substances 0.000 description 3
- 235000019438 castor oil Nutrition 0.000 description 3
- 239000002299 complementary DNA Substances 0.000 description 3
- 235000013365 dairy product Nutrition 0.000 description 3
- LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 3
- 230000001747 exhibiting effect Effects 0.000 description 3
- 238000002474 experimental method Methods 0.000 description 3
- 235000013355 food flavoring agent Nutrition 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 239000000499 gel Substances 0.000 description 3
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 description 3
- 229940075529 glyceryl stearate Drugs 0.000 description 3
- BXWNKGSJHAJOGX-UHFFFAOYSA-N hexadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCO BXWNKGSJHAJOGX-UHFFFAOYSA-N 0.000 description 3
- BTFJIXJJCSYFAL-UHFFFAOYSA-N icosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCO BTFJIXJJCSYFAL-UHFFFAOYSA-N 0.000 description 3
- 230000005764 inhibitory process Effects 0.000 description 3
- 229910052500 inorganic mineral Inorganic materials 0.000 description 3
- 239000008101 lactose Substances 0.000 description 3
- 239000000314 lubricant Substances 0.000 description 3
- 235000019359 magnesium stearate Nutrition 0.000 description 3
- HEBKCHPVOIAQTA-UHFFFAOYSA-N meso ribitol Natural products OCC(O)C(O)C(O)CO HEBKCHPVOIAQTA-UHFFFAOYSA-N 0.000 description 3
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 3
- 235000010755 mineral Nutrition 0.000 description 3
- 239000011707 mineral Substances 0.000 description 3
- 239000002480 mineral oil Substances 0.000 description 3
- 235000010446 mineral oil Nutrition 0.000 description 3
- 238000002156 mixing Methods 0.000 description 3
- 230000003020 moisturizing effect Effects 0.000 description 3
- 235000015097 nutrients Nutrition 0.000 description 3
- 150000007524 organic acids Chemical class 0.000 description 3
- 239000002953 phosphate buffered saline Substances 0.000 description 3
- 239000003755 preservative agent Substances 0.000 description 3
- QELSKZZBTMNZEB-UHFFFAOYSA-N propylparaben Chemical compound CCCOC(=O)C1=CC=C(O)C=C1 QELSKZZBTMNZEB-UHFFFAOYSA-N 0.000 description 3
- 239000008213 purified water Substances 0.000 description 3
- 239000002904 solvent Substances 0.000 description 3
- 239000000600 sorbitol Substances 0.000 description 3
- 229960002920 sorbitol Drugs 0.000 description 3
- 235000010356 sorbitol Nutrition 0.000 description 3
- 239000008107 starch Substances 0.000 description 3
- 235000019698 starch Nutrition 0.000 description 3
- 229940032147 starch Drugs 0.000 description 3
- 239000002562 thickening agent Substances 0.000 description 3
- 235000015112 vegetable and seed oil Nutrition 0.000 description 3
- 150000003722 vitamin derivatives Chemical class 0.000 description 3
- 239000000811 xylitol Substances 0.000 description 3
- 235000010447 xylitol Nutrition 0.000 description 3
- 229960002675 xylitol Drugs 0.000 description 3
- HEBKCHPVOIAQTA-SCDXWVJYSA-N xylitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)CO HEBKCHPVOIAQTA-SCDXWVJYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- JNYAEWCLZODPBN-JGWLITMVSA-N (2r,3r,4s)-2-[(1r)-1,2-dihydroxyethyl]oxolane-3,4-diol Chemical compound OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O JNYAEWCLZODPBN-JGWLITMVSA-N 0.000 description 2
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 2
- GVJHHUAWPYXKBD-UHFFFAOYSA-N (±)-α-Tocopherol Chemical compound OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C GVJHHUAWPYXKBD-UHFFFAOYSA-N 0.000 description 2
- WNWHHMBRJJOGFJ-UHFFFAOYSA-N 16-methylheptadecan-1-ol Chemical compound CC(C)CCCCCCCCCCCCCCCO WNWHHMBRJJOGFJ-UHFFFAOYSA-N 0.000 description 2
- SVTBMSDMJJWYQN-UHFFFAOYSA-N 2-methylpentane-2,4-diol Chemical compound CC(O)CC(C)(C)O SVTBMSDMJJWYQN-UHFFFAOYSA-N 0.000 description 2
- QFOHBWFCKVYLES-UHFFFAOYSA-N Butylparaben Chemical compound CCCCOC(=O)C1=CC=C(O)C=C1 QFOHBWFCKVYLES-UHFFFAOYSA-N 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 229920002261 Corn starch Polymers 0.000 description 2
- 102000005636 Cyclic AMP Response Element-Binding Protein Human genes 0.000 description 2
- 108010045171 Cyclic AMP Response Element-Binding Protein Proteins 0.000 description 2
- 102000008130 Cyclic AMP-Dependent Protein Kinases Human genes 0.000 description 2
- 108010049894 Cyclic AMP-Dependent Protein Kinases Proteins 0.000 description 2
- ZZZCUOFIHGPKAK-UHFFFAOYSA-N D-erythro-ascorbic acid Natural products OCC1OC(=O)C(O)=C1O ZZZCUOFIHGPKAK-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- XMSXQFUHVRWGNA-UHFFFAOYSA-N Decamethylcyclopentasiloxane Chemical compound C[Si]1(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O[Si](C)(C)O1 XMSXQFUHVRWGNA-UHFFFAOYSA-N 0.000 description 2
- 239000004375 Dextrin Substances 0.000 description 2
- 229920001353 Dextrin Polymers 0.000 description 2
- 239000004386 Erythritol Substances 0.000 description 2
- UNXHWFMMPAWVPI-UHFFFAOYSA-N Erythritol Natural products OCC(O)C(O)CO UNXHWFMMPAWVPI-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 108010010803 Gelatin Proteins 0.000 description 2
- AEMRFAOFKBGASW-UHFFFAOYSA-N Glycolic acid Chemical compound OCC(O)=O AEMRFAOFKBGASW-UHFFFAOYSA-N 0.000 description 2
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 2
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical compound [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- 238000010222 PCR analysis Methods 0.000 description 2
- 229910019142 PO4 Inorganic materials 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- 239000004698 Polyethylene Substances 0.000 description 2
- 229920001214 Polysorbate 60 Polymers 0.000 description 2
- 229920002125 Sokalan® Polymers 0.000 description 2
- HVUMOYIDDBPOLL-XWVZOOPGSA-N Sorbitan monostearate Chemical compound CCCCCCCCCCCCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O HVUMOYIDDBPOLL-XWVZOOPGSA-N 0.000 description 2
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 2
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- 102000008314 Type 1 Melanocortin Receptor Human genes 0.000 description 2
- 108010021428 Type 1 Melanocortin Receptor Proteins 0.000 description 2
- 229930003268 Vitamin C Natural products 0.000 description 2
- XLOMVQKBTHCTTD-UHFFFAOYSA-N Zinc monoxide Chemical compound [Zn]=O XLOMVQKBTHCTTD-UHFFFAOYSA-N 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 239000002671 adjuvant Substances 0.000 description 2
- 150000001298 alcohols Chemical class 0.000 description 2
- IAJILQKETJEXLJ-QTBDOELSSA-N aldehydo-D-glucuronic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-QTBDOELSSA-N 0.000 description 2
- 235000010443 alginic acid Nutrition 0.000 description 2
- 229920000615 alginic acid Polymers 0.000 description 2
- 229910052783 alkali metal Inorganic materials 0.000 description 2
- 150000001340 alkali metals Chemical class 0.000 description 2
- 229910052784 alkaline earth metal Inorganic materials 0.000 description 2
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 2
- 239000008346 aqueous phase Substances 0.000 description 2
- 239000007864 aqueous solution Substances 0.000 description 2
- 239000003125 aqueous solvent Substances 0.000 description 2
- 229960005070 ascorbic acid Drugs 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 2
- 235000014121 butter Nutrition 0.000 description 2
- 229910002091 carbon monoxide Inorganic materials 0.000 description 2
- 229960000541 cetyl alcohol Drugs 0.000 description 2
- 235000019219 chocolate Nutrition 0.000 description 2
- 235000009508 confectionery Nutrition 0.000 description 2
- 239000008120 corn starch Substances 0.000 description 2
- 235000019425 dextrin Nutrition 0.000 description 2
- NOPFSRXAKWQILS-UHFFFAOYSA-N docosan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCCCCCO NOPFSRXAKWQILS-UHFFFAOYSA-N 0.000 description 2
- 239000003937 drug carrier Substances 0.000 description 2
- UNXHWFMMPAWVPI-ZXZARUISSA-N erythritol Chemical compound OC[C@H](O)[C@H](O)CO UNXHWFMMPAWVPI-ZXZARUISSA-N 0.000 description 2
- 235000019414 erythritol Nutrition 0.000 description 2
- 229940009714 erythritol Drugs 0.000 description 2
- 239000006260 foam Substances 0.000 description 2
- 235000015203 fruit juice Nutrition 0.000 description 2
- 239000008273 gelatin Substances 0.000 description 2
- 229920000159 gelatin Polymers 0.000 description 2
- 239000007903 gelatin capsule Substances 0.000 description 2
- 235000019322 gelatine Nutrition 0.000 description 2
- 235000011852 gelatine desserts Nutrition 0.000 description 2
- 239000008103 glucose Substances 0.000 description 2
- 229940097043 glucuronic acid Drugs 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- KWIUHFFTVRNATP-UHFFFAOYSA-N glycine betaine Chemical compound C[N+](C)(C)CC([O-])=O KWIUHFFTVRNATP-UHFFFAOYSA-N 0.000 description 2
- 239000008269 hand cream Substances 0.000 description 2
- 125000002887 hydroxy group Chemical group [H]O* 0.000 description 2
- 230000003834 intracellular effect Effects 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229940041476 lactose 100 mg Drugs 0.000 description 2
- 239000006193 liquid solution Substances 0.000 description 2
- 230000007774 longterm Effects 0.000 description 2
- 239000001630 malic acid Substances 0.000 description 2
- 235000011090 malic acid Nutrition 0.000 description 2
- 230000036564 melanin content Effects 0.000 description 2
- 229910052751 metal Inorganic materials 0.000 description 2
- 239000002184 metal Substances 0.000 description 2
- 235000013336 milk Nutrition 0.000 description 2
- 239000008267 milk Substances 0.000 description 2
- 210000004080 milk Anatomy 0.000 description 2
- 150000007522 mineralic acids Chemical class 0.000 description 2
- 229930014626 natural product Natural products 0.000 description 2
- 239000002417 nutraceutical Substances 0.000 description 2
- 235000021436 nutraceutical agent Nutrition 0.000 description 2
- GLDOVTGHNKAZLK-UHFFFAOYSA-N octadecan-1-ol Chemical compound CCCCCCCCCCCCCCCCCCO GLDOVTGHNKAZLK-UHFFFAOYSA-N 0.000 description 2
- QIQXTHQIDYTFRH-UHFFFAOYSA-N octadecanoic acid Chemical compound CCCCCCCCCCCCCCCCCC(O)=O QIQXTHQIDYTFRH-UHFFFAOYSA-N 0.000 description 2
- 229920001542 oligosaccharide Polymers 0.000 description 2
- 150000002482 oligosaccharides Chemical class 0.000 description 2
- 239000004006 olive oil Substances 0.000 description 2
- 235000008390 olive oil Nutrition 0.000 description 2
- 238000001543 one-way ANOVA Methods 0.000 description 2
- 239000003961 penetration enhancing agent Substances 0.000 description 2
- 239000000825 pharmaceutical preparation Substances 0.000 description 2
- 239000010452 phosphate Substances 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 2
- 150000003904 phospholipids Chemical class 0.000 description 2
- 230000019612 pigmentation Effects 0.000 description 2
- 239000006187 pill Substances 0.000 description 2
- 229920000573 polyethylene Polymers 0.000 description 2
- 229920000136 polysorbate Polymers 0.000 description 2
- 229960003415 propylparaben Drugs 0.000 description 2
- 108090000623 proteins and genes Proteins 0.000 description 2
- LXNHXLLTXMVWPM-UHFFFAOYSA-N pyridoxine Chemical compound CC1=NC=C(CO)C(CO)=C1O LXNHXLLTXMVWPM-UHFFFAOYSA-N 0.000 description 2
- 239000003642 reactive oxygen metabolite Substances 0.000 description 2
- 238000003753 real-time PCR Methods 0.000 description 2
- 230000002829 reductive effect Effects 0.000 description 2
- 238000010839 reverse transcription Methods 0.000 description 2
- 239000002453 shampoo Substances 0.000 description 2
- SQGYOTSLMSWVJD-UHFFFAOYSA-N silver(1+) nitrate Chemical compound [Ag+].[O-]N(=O)=O SQGYOTSLMSWVJD-UHFFFAOYSA-N 0.000 description 2
- 239000000344 soap Substances 0.000 description 2
- 229950011392 sorbitan stearate Drugs 0.000 description 2
- 239000007921 spray Substances 0.000 description 2
- PRAKJMSDJKAYCZ-UHFFFAOYSA-N squalane Chemical compound CC(C)CCCC(C)CCCC(C)CCCCC(C)CCCC(C)CCCC(C)C PRAKJMSDJKAYCZ-UHFFFAOYSA-N 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000829 suppository Substances 0.000 description 2
- 230000002195 synergetic effect Effects 0.000 description 2
- 239000000454 talc Substances 0.000 description 2
- 229910052623 talc Inorganic materials 0.000 description 2
- 235000012222 talc Nutrition 0.000 description 2
- 239000011975 tartaric acid Substances 0.000 description 2
- 235000002906 tartaric acid Nutrition 0.000 description 2
- XOAAWQZATWQOTB-UHFFFAOYSA-N taurine Chemical compound NCCS(O)(=O)=O XOAAWQZATWQOTB-UHFFFAOYSA-N 0.000 description 2
- JOXIMZWYDAKGHI-UHFFFAOYSA-N toluene-4-sulfonic acid Chemical compound CC1=CC=C(S(O)(=O)=O)C=C1 JOXIMZWYDAKGHI-UHFFFAOYSA-N 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- 239000008158 vegetable oil Substances 0.000 description 2
- 235000019154 vitamin C Nutrition 0.000 description 2
- 239000011718 vitamin C Substances 0.000 description 2
- 239000000080 wetting agent Substances 0.000 description 2
- MXOAEAUPQDYUQM-QMMMGPOBSA-N (S)-chlorphenesin Chemical compound OC[C@H](O)COC1=CC=C(Cl)C=C1 MXOAEAUPQDYUQM-QMMMGPOBSA-N 0.000 description 1
- FFJCNSLCJOQHKM-CLFAGFIQSA-N (z)-1-[(z)-octadec-9-enoxy]octadec-9-ene Chemical compound CCCCCCCC\C=C/CCCCCCCCOCCCCCCCC\C=C/CCCCCCCC FFJCNSLCJOQHKM-CLFAGFIQSA-N 0.000 description 1
- 229940058015 1,3-butylene glycol Drugs 0.000 description 1
- RTBFRGCFXZNCOE-UHFFFAOYSA-N 1-methylsulfonylpiperidin-4-one Chemical compound CS(=O)(=O)N1CCC(=O)CC1 RTBFRGCFXZNCOE-UHFFFAOYSA-N 0.000 description 1
- IIZPXYDJLKNOIY-JXPKJXOSSA-N 1-palmitoyl-2-arachidonoyl-sn-glycero-3-phosphocholine Chemical compound CCCCCCCCCCCCCCCC(=O)OC[C@H](COP([O-])(=O)OCC[N+](C)(C)C)OC(=O)CCC\C=C/C\C=C/C\C=C/C\C=C/CCCCC IIZPXYDJLKNOIY-JXPKJXOSSA-N 0.000 description 1
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 description 1
- VZSRBBMJRBPUNF-UHFFFAOYSA-N 2-(2,3-dihydro-1H-inden-2-ylamino)-N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]pyrimidine-5-carboxamide Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C(=O)NCCC(N1CC2=C(CC1)NN=N2)=O VZSRBBMJRBPUNF-UHFFFAOYSA-N 0.000 description 1
- XNWFRZJHXBZDAG-UHFFFAOYSA-N 2-METHOXYETHANOL Chemical compound COCCO XNWFRZJHXBZDAG-UHFFFAOYSA-N 0.000 description 1
- LCVHZNSIAYNAGX-UHFFFAOYSA-N 2-ethylhexyl 3,5,5-trimethylhexanoate Chemical compound CCCCC(CC)COC(=O)CC(C)CC(C)(C)C LCVHZNSIAYNAGX-UHFFFAOYSA-N 0.000 description 1
- LEACJMVNYZDSKR-UHFFFAOYSA-N 2-octyldodecan-1-ol Chemical compound CCCCCCCCCCC(CO)CCCCCCCC LEACJMVNYZDSKR-UHFFFAOYSA-N 0.000 description 1
- BGRXBNZMPMGLQI-UHFFFAOYSA-N 2-octyldodecyl tetradecanoate Chemical compound CCCCCCCCCCCCCC(=O)OCC(CCCCCCCC)CCCCCCCCCC BGRXBNZMPMGLQI-UHFFFAOYSA-N 0.000 description 1
- QCDWFXQBSFUVSP-UHFFFAOYSA-N 2-phenoxyethanol Chemical compound OCCOC1=CC=CC=C1 QCDWFXQBSFUVSP-UHFFFAOYSA-N 0.000 description 1
- 108020005065 3' Flanking Region Proteins 0.000 description 1
- QULIOZDJZXKLNY-UHFFFAOYSA-N 3,4,5-trihydroxy-2-propylbenzoic acid Chemical compound CCCC1=C(O)C(O)=C(O)C=C1C(O)=O QULIOZDJZXKLNY-UHFFFAOYSA-N 0.000 description 1
- YLZOPXRUQYQQID-UHFFFAOYSA-N 3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)-1-[4-[2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidin-5-yl]piperazin-1-yl]propan-1-one Chemical compound N1N=NC=2CN(CCC=21)CCC(=O)N1CCN(CC1)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F YLZOPXRUQYQQID-UHFFFAOYSA-N 0.000 description 1
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- BNNMDMGPZUOOOE-UHFFFAOYSA-N 4-methylbenzenesulfonic acid Chemical class CC1=CC=C(S(O)(=O)=O)C=C1.CC1=CC=C(S(O)(=O)=O)C=C1 BNNMDMGPZUOOOE-UHFFFAOYSA-N 0.000 description 1
- 108020005029 5' Flanking Region Proteins 0.000 description 1
- DEXFNLNNUZKHNO-UHFFFAOYSA-N 6-[3-[4-[2-(2,3-dihydro-1H-inden-2-ylamino)pyrimidin-5-yl]piperidin-1-yl]-3-oxopropyl]-3H-1,3-benzoxazol-2-one Chemical compound C1C(CC2=CC=CC=C12)NC1=NC=C(C=N1)C1CCN(CC1)C(CCC1=CC2=C(NC(O2)=O)C=C1)=O DEXFNLNNUZKHNO-UHFFFAOYSA-N 0.000 description 1
- FHVDTGUDJYJELY-UHFFFAOYSA-N 6-{[2-carboxy-4,5-dihydroxy-6-(phosphanyloxy)oxan-3-yl]oxy}-4,5-dihydroxy-3-phosphanyloxane-2-carboxylic acid Chemical compound O1C(C(O)=O)C(P)C(O)C(O)C1OC1C(C(O)=O)OC(OP)C(O)C1O FHVDTGUDJYJELY-UHFFFAOYSA-N 0.000 description 1
- QTBSBXVTEAMEQO-UHFFFAOYSA-M Acetate Chemical compound CC([O-])=O QTBSBXVTEAMEQO-UHFFFAOYSA-M 0.000 description 1
- NIXOWILDQLNWCW-UHFFFAOYSA-N Acrylic acid Chemical compound OC(=O)C=C NIXOWILDQLNWCW-UHFFFAOYSA-N 0.000 description 1
- 244000080767 Areca catechu Species 0.000 description 1
- 235000006226 Areca catechu Nutrition 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- DHFUFHYLYSCIJY-WSGIOKLISA-N CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O Chemical compound CCCCCCCCCCCCCCCCCCCCO[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O DHFUFHYLYSCIJY-WSGIOKLISA-N 0.000 description 1
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 description 1
- 229920002134 Carboxymethyl cellulose Polymers 0.000 description 1
- PTHCMJGKKRQCBF-UHFFFAOYSA-N Cellulose, microcrystalline Chemical compound OC1C(O)C(OC)OC(CO)C1OC1C(O)C(O)C(OC)C(CO)O1 PTHCMJGKKRQCBF-UHFFFAOYSA-N 0.000 description 1
- KRKNYBCHXYNGOX-UHFFFAOYSA-K Citrate Chemical compound [O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O KRKNYBCHXYNGOX-UHFFFAOYSA-K 0.000 description 1
- 229920000858 Cyclodextrin Polymers 0.000 description 1
- AUNGANRZJHBGPY-UHFFFAOYSA-N D-Lyxoflavin Natural products OCC(O)C(O)C(O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-UHFFFAOYSA-N 0.000 description 1
- FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
- ZAKOWWREFLAJOT-CEFNRUSXSA-N D-alpha-tocopherylacetate Chemical compound CC(=O)OC1=C(C)C(C)=C2O[C@@](CCC[C@H](C)CCC[C@H](C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-CEFNRUSXSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- 108091035710 E-box Proteins 0.000 description 1
- LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
- 206010014970 Ephelides Diseases 0.000 description 1
- LYCAIKOWRPUZTN-UHFFFAOYSA-N Ethylene glycol Chemical compound OCCO LYCAIKOWRPUZTN-UHFFFAOYSA-N 0.000 description 1
- 239000004606 Fillers/Extenders Substances 0.000 description 1
- 229930091371 Fructose Natural products 0.000 description 1
- 239000005715 Fructose Substances 0.000 description 1
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 description 1
- WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 1
- 102000001554 Hemoglobins Human genes 0.000 description 1
- 108010054147 Hemoglobins Proteins 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- 102100034343 Integrase Human genes 0.000 description 1
- CKLJMWTZIZZHCS-REOHCLBHSA-N L-aspartic acid Chemical compound OC(=O)[C@@H](N)CC(O)=O CKLJMWTZIZZHCS-REOHCLBHSA-N 0.000 description 1
- WHUUTDBJXJRKMK-VKHMYHEASA-N L-glutamic acid Chemical compound OC(=O)[C@@H](N)CCC(O)=O WHUUTDBJXJRKMK-VKHMYHEASA-N 0.000 description 1
- HNDVDQJCIGZPNO-YFKPBYRVSA-N L-histidine Chemical compound OC(=O)[C@@H](N)CC1=CN=CN1 HNDVDQJCIGZPNO-YFKPBYRVSA-N 0.000 description 1
- JVTAAEKCZFNVCJ-UHFFFAOYSA-M Lactate Chemical compound CC(O)C([O-])=O JVTAAEKCZFNVCJ-UHFFFAOYSA-M 0.000 description 1
- 240000008415 Lactuca sativa Species 0.000 description 1
- 235000003228 Lactuca sativa Nutrition 0.000 description 1
- 240000007472 Leucaena leucocephala Species 0.000 description 1
- 235000010643 Leucaena leucocephala Nutrition 0.000 description 1
- UPYKUZBSLRQECL-UKMVMLAPSA-N Lycopene Natural products CC(=C/C=C/C=C(C)/C=C/C=C(C)/C=C/C1C(=C)CCCC1(C)C)C=CC=C(/C)C=CC2C(=C)CCCC2(C)C UPYKUZBSLRQECL-UKMVMLAPSA-N 0.000 description 1
- 235000018330 Macadamia integrifolia Nutrition 0.000 description 1
- 240000000912 Macadamia tetraphylla Species 0.000 description 1
- 235000003800 Macadamia tetraphylla Nutrition 0.000 description 1
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 description 1
- 229930195725 Mannitol Natural products 0.000 description 1
- 208000003351 Melanosis Diseases 0.000 description 1
- 229920000168 Microcrystalline cellulose Polymers 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- 240000000249 Morus alba Species 0.000 description 1
- 235000008708 Morus alba Nutrition 0.000 description 1
- MKYBYDHXWVHEJW-UHFFFAOYSA-N N-[1-oxo-1-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propan-2-yl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(C(C)NC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 MKYBYDHXWVHEJW-UHFFFAOYSA-N 0.000 description 1
- NIPNSKYNPDTRPC-UHFFFAOYSA-N N-[2-oxo-2-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)ethyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 NIPNSKYNPDTRPC-UHFFFAOYSA-N 0.000 description 1
- AFCARXCZXQIEQB-UHFFFAOYSA-N N-[3-oxo-3-(2,4,6,7-tetrahydrotriazolo[4,5-c]pyridin-5-yl)propyl]-2-[[3-(trifluoromethoxy)phenyl]methylamino]pyrimidine-5-carboxamide Chemical compound O=C(CCNC(=O)C=1C=NC(=NC=1)NCC1=CC(=CC=C1)OC(F)(F)F)N1CC2=C(CC1)NN=N2 AFCARXCZXQIEQB-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 240000007594 Oryza sativa Species 0.000 description 1
- 235000007164 Oryza sativa Nutrition 0.000 description 1
- 229920002230 Pectic acid Polymers 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-L Phosphate ion(2-) Chemical compound OP([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-L 0.000 description 1
- 239000002202 Polyethylene glycol Substances 0.000 description 1
- 239000004743 Polypropylene Substances 0.000 description 1
- 239000004372 Polyvinyl alcohol Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 239000013614 RNA sample Substances 0.000 description 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 description 1
- AUNGANRZJHBGPY-SCRDCRAPSA-N Riboflavin Chemical compound OC[C@@H](O)[C@@H](O)[C@@H](O)CN1C=2C=C(C)C(C)=CC=2N=C2C1=NC(=O)NC2=O AUNGANRZJHBGPY-SCRDCRAPSA-N 0.000 description 1
- 206010040829 Skin discolouration Diseases 0.000 description 1
- 206010040865 Skin hyperpigmentation Diseases 0.000 description 1
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 1
- 229920002385 Sodium hyaluronate Polymers 0.000 description 1
- 244000061458 Solanum melongena Species 0.000 description 1
- 235000002597 Solanum melongena Nutrition 0.000 description 1
- NWGKJDSIEKMTRX-AAZCQSIUSA-N Sorbitan monooleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OC[C@@H](O)[C@H]1OC[C@H](O)[C@H]1O NWGKJDSIEKMTRX-AAZCQSIUSA-N 0.000 description 1
- 235000021355 Stearic acid Nutrition 0.000 description 1
- 244000269722 Thea sinensis Species 0.000 description 1
- 235000005764 Theobroma cacao ssp. cacao Nutrition 0.000 description 1
- 235000005767 Theobroma cacao ssp. sphaerocarpum Nutrition 0.000 description 1
- GSEJCLTVZPLZKY-UHFFFAOYSA-N Triethanolamine Chemical compound OCCN(CCO)CCO GSEJCLTVZPLZKY-UHFFFAOYSA-N 0.000 description 1
- 229930003451 Vitamin B1 Natural products 0.000 description 1
- 229930003779 Vitamin B12 Natural products 0.000 description 1
- 229930003471 Vitamin B2 Natural products 0.000 description 1
- 229930003427 Vitamin E Natural products 0.000 description 1
- 235000009392 Vitis Nutrition 0.000 description 1
- 241000219095 Vitis Species 0.000 description 1
- 238000002835 absorbance Methods 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 102000030621 adenylate cyclase Human genes 0.000 description 1
- 108060000200 adenylate cyclase Proteins 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000000443 aerosol Substances 0.000 description 1
- 235000013334 alcoholic beverage Nutrition 0.000 description 1
- IAJILQKETJEXLJ-RSJOWCBRSA-N aldehydo-D-galacturonic acid Chemical compound O=C[C@H](O)[C@@H](O)[C@@H](O)[C@H](O)C(O)=O IAJILQKETJEXLJ-RSJOWCBRSA-N 0.000 description 1
- 229940072056 alginate Drugs 0.000 description 1
- 239000000783 alginic acid Substances 0.000 description 1
- 229960001126 alginic acid Drugs 0.000 description 1
- 150000004781 alginic acids Chemical class 0.000 description 1
- 150000008044 alkali metal hydroxides Chemical class 0.000 description 1
- 229910001860 alkaline earth metal hydroxide Inorganic materials 0.000 description 1
- 150000001336 alkenes Chemical class 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- SNAAJJQQZSMGQD-UHFFFAOYSA-N aluminum magnesium Chemical compound [Mg].[Al] SNAAJJQQZSMGQD-UHFFFAOYSA-N 0.000 description 1
- 125000003277 amino group Chemical group 0.000 description 1
- 239000002280 amphoteric surfactant Substances 0.000 description 1
- 238000004458 analytical method Methods 0.000 description 1
- JFCQEDHGNNZCLN-UHFFFAOYSA-N anhydrous glutaric acid Natural products OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 description 1
- 239000003945 anionic surfactant Substances 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 230000002421 anti-septic effect Effects 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 239000011260 aqueous acid Substances 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 235000003704 aspartic acid Nutrition 0.000 description 1
- 239000012752 auxiliary agent Substances 0.000 description 1
- 210000000270 basal cell Anatomy 0.000 description 1
- 230000008901 benefit Effects 0.000 description 1
- 239000000440 bentonite Substances 0.000 description 1
- 229910000278 bentonite Inorganic materials 0.000 description 1
- 229940092782 bentonite Drugs 0.000 description 1
- SVPXDRXYRYOSEX-UHFFFAOYSA-N bentoquatam Chemical compound O.O=[Si]=O.O=[Al]O[Al]=O SVPXDRXYRYOSEX-UHFFFAOYSA-N 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- OQFSQFPPLPISGP-UHFFFAOYSA-N beta-carboxyaspartic acid Natural products OC(=O)C(N)C(C(O)=O)C(O)=O OQFSQFPPLPISGP-UHFFFAOYSA-N 0.000 description 1
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 description 1
- 229960003237 betaine Drugs 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000033228 biological regulation Effects 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 235000015895 biscuits Nutrition 0.000 description 1
- 210000004204 blood vessel Anatomy 0.000 description 1
- 235000008429 bread Nutrition 0.000 description 1
- 239000000872 buffer Substances 0.000 description 1
- 235000019437 butane-1,3-diol Nutrition 0.000 description 1
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 description 1
- 229940067596 butylparaben Drugs 0.000 description 1
- 235000001046 cacaotero Nutrition 0.000 description 1
- 235000012970 cakes Nutrition 0.000 description 1
- 235000001465 calcium Nutrition 0.000 description 1
- 229910052791 calcium Inorganic materials 0.000 description 1
- 239000011575 calcium Substances 0.000 description 1
- FAPWYRCQGJNNSJ-UBKPKTQASA-L calcium D-pantothenic acid Chemical compound [Ca+2].OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O.OCC(C)(C)[C@@H](O)C(=O)NCCC([O-])=O FAPWYRCQGJNNSJ-UBKPKTQASA-L 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 229940037769 calcium carbonate 100 mg Drugs 0.000 description 1
- 229960002079 calcium pantothenate Drugs 0.000 description 1
- 239000001506 calcium phosphate Substances 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 235000011010 calcium phosphates Nutrition 0.000 description 1
- 159000000007 calcium salts Chemical class 0.000 description 1
- 239000000378 calcium silicate Substances 0.000 description 1
- 229910052918 calcium silicate Inorganic materials 0.000 description 1
- 235000012241 calcium silicate Nutrition 0.000 description 1
- OYACROKNLOSFPA-UHFFFAOYSA-N calcium;dioxido(oxo)silane Chemical compound [Ca+2].[O-][Si]([O-])=O OYACROKNLOSFPA-UHFFFAOYSA-N 0.000 description 1
- 229960001631 carbomer Drugs 0.000 description 1
- 125000004432 carbon atom Chemical group C* 0.000 description 1
- 235000014171 carbonated beverage Nutrition 0.000 description 1
- BVKZGUZCCUSVTD-UHFFFAOYSA-N carbonic acid Chemical compound OC(O)=O BVKZGUZCCUSVTD-UHFFFAOYSA-N 0.000 description 1
- 239000001768 carboxy methyl cellulose Substances 0.000 description 1
- 235000010948 carboxy methyl cellulose Nutrition 0.000 description 1
- 150000001746 carotenes Chemical class 0.000 description 1
- 235000005473 carotenes Nutrition 0.000 description 1
- 229960001777 castor oil Drugs 0.000 description 1
- 239000003093 cationic surfactant Substances 0.000 description 1
- 238000004113 cell culture Methods 0.000 description 1
- 239000001913 cellulose Substances 0.000 description 1
- 235000010980 cellulose Nutrition 0.000 description 1
- 229920002678 cellulose Polymers 0.000 description 1
- 229940073639 ceteareth-6 Drugs 0.000 description 1
- 235000013351 cheese Nutrition 0.000 description 1
- 229960003993 chlorphenesin Drugs 0.000 description 1
- 230000001684 chronic effect Effects 0.000 description 1
- 229940069647 citric acid 1000 mg Drugs 0.000 description 1
- 229940021231 clearskin Drugs 0.000 description 1
- AGVAZMGAQJOSFJ-WZHZPDAFSA-M cobalt(2+);[(2r,3s,4r,5s)-5-(5,6-dimethylbenzimidazol-1-yl)-4-hydroxy-2-(hydroxymethyl)oxolan-3-yl] [(2r)-1-[3-[(1r,2r,3r,4z,7s,9z,12s,13s,14z,17s,18s,19r)-2,13,18-tris(2-amino-2-oxoethyl)-7,12,17-tris(3-amino-3-oxopropyl)-3,5,8,8,13,15,18,19-octamethyl-2 Chemical compound [Co+2].N#[C-].[N-]([C@@H]1[C@H](CC(N)=O)[C@@]2(C)CCC(=O)NC[C@@H](C)OP(O)(=O)O[C@H]3[C@H]([C@H](O[C@@H]3CO)N3C4=CC(C)=C(C)C=C4N=C3)O)\C2=C(C)/C([C@H](C\2(C)C)CCC(N)=O)=N/C/2=C\C([C@H]([C@@]/2(CC(N)=O)C)CCC(N)=O)=N\C\2=C(C)/C2=N[C@]1(C)[C@@](C)(CC(N)=O)[C@@H]2CCC(N)=O AGVAZMGAQJOSFJ-WZHZPDAFSA-M 0.000 description 1
- 239000000084 colloidal system Substances 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000004040 coloring Methods 0.000 description 1
- 238000013329 compounding Methods 0.000 description 1
- 239000012141 concentrate Substances 0.000 description 1
- 235000008504 concentrate Nutrition 0.000 description 1
- 238000012790 confirmation Methods 0.000 description 1
- 229940086555 cyclomethicone Drugs 0.000 description 1
- ZAKOWWREFLAJOT-UHFFFAOYSA-N d-alpha-Tocopheryl acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1C ZAKOWWREFLAJOT-UHFFFAOYSA-N 0.000 description 1
- 239000003405 delayed action preparation Substances 0.000 description 1
- 238000001514 detection method Methods 0.000 description 1
- 239000008121 dextrose Substances 0.000 description 1
- 235000014113 dietary fatty acids Nutrition 0.000 description 1
- 229940105990 diglycerin Drugs 0.000 description 1
- GPLRAVKSCUXZTP-UHFFFAOYSA-N diglycerol Chemical compound OCC(O)COCC(O)CO GPLRAVKSCUXZTP-UHFFFAOYSA-N 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-M dihydrogenphosphate Chemical compound OP(O)([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-M 0.000 description 1
- 229940008099 dimethicone Drugs 0.000 description 1
- 239000004205 dimethyl polysiloxane Substances 0.000 description 1
- 235000013870 dimethyl polysiloxane Nutrition 0.000 description 1
- 150000002016 disaccharides Chemical class 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 230000006806 disease prevention Effects 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229960000735 docosanol Drugs 0.000 description 1
- 239000002552 dosage form Substances 0.000 description 1
- 239000006196 drop Substances 0.000 description 1
- 229940126534 drug product Drugs 0.000 description 1
- 238000001035 drying Methods 0.000 description 1
- 229920001971 elastomer Polymers 0.000 description 1
- 239000003792 electrolyte Substances 0.000 description 1
- 230000001804 emulsifying effect Effects 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 235000020774 essential nutrients Nutrition 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
- 229940093471 ethyl oleate Drugs 0.000 description 1
- 229940100549 ethylhexyl isononanoate Drugs 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 238000001704 evaporation Methods 0.000 description 1
- 230000006355 external stress Effects 0.000 description 1
- 239000004744 fabric Substances 0.000 description 1
- 239000000194 fatty acid Substances 0.000 description 1
- 229930195729 fatty acid Natural products 0.000 description 1
- 150000004665 fatty acids Chemical class 0.000 description 1
- 239000011790 ferrous sulphate Substances 0.000 description 1
- 235000003891 ferrous sulphate Nutrition 0.000 description 1
- 230000001605 fetal effect Effects 0.000 description 1
- 239000000706 filtrate Substances 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 229940095463 folic acid 0.5 mg Drugs 0.000 description 1
- 235000012041 food component Nutrition 0.000 description 1
- 239000005417 food ingredient Substances 0.000 description 1
- 235000003599 food sweetener Nutrition 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- WIGCFUFOHFEKBI-UHFFFAOYSA-N gamma-tocopherol Natural products CC(C)CCCC(C)CCCC(C)CCCC1CCC2C(C)C(O)C(C)C(C)C2O1 WIGCFUFOHFEKBI-UHFFFAOYSA-N 0.000 description 1
- FOYKKGHVWRFIBD-UHFFFAOYSA-N gamma-tocopherol acetate Natural products CC(=O)OC1=C(C)C(C)=C2OC(CCCC(C)CCCC(C)CCCC(C)C)(C)CCC2=C1 FOYKKGHVWRFIBD-UHFFFAOYSA-N 0.000 description 1
- 235000020710 ginseng extract Nutrition 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 235000013922 glutamic acid Nutrition 0.000 description 1
- 239000004220 glutamic acid Substances 0.000 description 1
- 235000020688 green tea extract Nutrition 0.000 description 1
- 229940093915 gynecological organic acid Drugs 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 241000411851 herbal medicine Species 0.000 description 1
- IPCSVZSSVZVIGE-UHFFFAOYSA-M hexadecanoate Chemical compound CCCCCCCCCCCCCCCC([O-])=O IPCSVZSSVZVIGE-UHFFFAOYSA-M 0.000 description 1
- 229940051250 hexylene glycol Drugs 0.000 description 1
- HNDVDQJCIGZPNO-UHFFFAOYSA-N histidine Natural products OC(=O)C(N)CC1=CN=CN1 HNDVDQJCIGZPNO-UHFFFAOYSA-N 0.000 description 1
- 239000005556 hormone Substances 0.000 description 1
- 229940088597 hormone Drugs 0.000 description 1
- XMBWDFGMSWQBCA-UHFFFAOYSA-N hydrogen iodide Chemical compound I XMBWDFGMSWQBCA-UHFFFAOYSA-N 0.000 description 1
- QAOWNCQODCNURD-UHFFFAOYSA-M hydrogensulfate Chemical compound OS([O-])(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-M 0.000 description 1
- 229940071870 hydroiodic acid Drugs 0.000 description 1
- 235000015243 ice cream Nutrition 0.000 description 1
- ZCTXEAQXZGPWFG-UHFFFAOYSA-N imidurea Chemical compound O=C1NC(=O)N(CO)C1NC(=O)NCNC(=O)NC1C(=O)NC(=O)N1CO ZCTXEAQXZGPWFG-UHFFFAOYSA-N 0.000 description 1
- 235000020344 instant tea Nutrition 0.000 description 1
- BAUYGSIQEAFULO-UHFFFAOYSA-L iron(2+) sulfate (anhydrous) Chemical compound [Fe+2].[O-]S([O-])(=O)=O BAUYGSIQEAFULO-UHFFFAOYSA-L 0.000 description 1
- 229910000359 iron(II) sulfate Inorganic materials 0.000 description 1
- 210000002510 keratinocyte Anatomy 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- VMPHSYLJUKZBJJ-UHFFFAOYSA-N lauric acid triglyceride Natural products CCCCCCCCCCCC(=O)OCC(OC(=O)CCCCCCCCCCC)COC(=O)CCCCCCCCCCC VMPHSYLJUKZBJJ-UHFFFAOYSA-N 0.000 description 1
- 239000000787 lecithin Substances 0.000 description 1
- 235000010445 lecithin Nutrition 0.000 description 1
- 229940067606 lecithin Drugs 0.000 description 1
- 229940069445 licorice extract Drugs 0.000 description 1
- 230000000670 limiting effect Effects 0.000 description 1
- 239000002502 liposome Substances 0.000 description 1
- 229940057995 liquid paraffin Drugs 0.000 description 1
- 229960003511 macrogol Drugs 0.000 description 1
- 229910052749 magnesium Inorganic materials 0.000 description 1
- 239000011777 magnesium Substances 0.000 description 1
- ZLNQQNXFFQJAID-UHFFFAOYSA-L magnesium carbonate Chemical compound [Mg+2].[O-]C([O-])=O ZLNQQNXFFQJAID-UHFFFAOYSA-L 0.000 description 1
- 239000001095 magnesium carbonate Substances 0.000 description 1
- 229910000021 magnesium carbonate Inorganic materials 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000000845 maltitol Substances 0.000 description 1
- 235000010449 maltitol Nutrition 0.000 description 1
- VQHSOMBJVWLPSR-WUJBLJFYSA-N maltitol Chemical compound OC[C@H](O)[C@@H](O)[C@@H]([C@H](O)CO)O[C@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O VQHSOMBJVWLPSR-WUJBLJFYSA-N 0.000 description 1
- 229940035436 maltitol Drugs 0.000 description 1
- IWYDHOAUDWTVEP-UHFFFAOYSA-M mandelate Chemical compound [O-]C(=O)C(O)C1=CC=CC=C1 IWYDHOAUDWTVEP-UHFFFAOYSA-M 0.000 description 1
- 239000000594 mannitol Substances 0.000 description 1
- 235000010355 mannitol Nutrition 0.000 description 1
- 229960001855 mannitol Drugs 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 235000013372 meat Nutrition 0.000 description 1
- 210000002780 melanosome Anatomy 0.000 description 1
- 238000002844 melting Methods 0.000 description 1
- 230000008018 melting Effects 0.000 description 1
- 102000006240 membrane receptors Human genes 0.000 description 1
- 108020004084 membrane receptors Proteins 0.000 description 1
- GXHMMDRXHUIUMN-UHFFFAOYSA-N methanesulfonic acid Chemical compound CS(O)(=O)=O.CS(O)(=O)=O GXHMMDRXHUIUMN-UHFFFAOYSA-N 0.000 description 1
- 229940098779 methanesulfonic acid Drugs 0.000 description 1
- 229920000609 methyl cellulose Polymers 0.000 description 1
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 1
- 239000001923 methylcellulose Substances 0.000 description 1
- 235000010981 methylcellulose Nutrition 0.000 description 1
- 229960002216 methylparaben Drugs 0.000 description 1
- 235000019813 microcrystalline cellulose Nutrition 0.000 description 1
- 239000008108 microcrystalline cellulose Substances 0.000 description 1
- 229940016286 microcrystalline cellulose Drugs 0.000 description 1
- 229940042472 mineral oil Drugs 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 150000002772 monosaccharides Chemical class 0.000 description 1
- JXTPJDDICSTXJX-UHFFFAOYSA-N n-Triacontane Natural products CCCCCCCCCCCCCCCCCCCCCCCCCCCCCC JXTPJDDICSTXJX-UHFFFAOYSA-N 0.000 description 1
- GOQYKNQRPGWPLP-UHFFFAOYSA-N n-heptadecyl alcohol Natural products CCCCCCCCCCCCCCCCCO GOQYKNQRPGWPLP-UHFFFAOYSA-N 0.000 description 1
- 230000003472 neutralizing effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 231100000957 no side effect Toxicity 0.000 description 1
- 239000002736 nonionic surfactant Substances 0.000 description 1
- 235000012149 noodles Nutrition 0.000 description 1
- 239000010466 nut oil Substances 0.000 description 1
- OQCDKBAXFALNLD-UHFFFAOYSA-N octadecanoic acid Natural products CCCCCCCC(C)CCCCCCCCC(O)=O OQCDKBAXFALNLD-UHFFFAOYSA-N 0.000 description 1
- KSCKTBJJRVPGKM-UHFFFAOYSA-N octan-1-olate;titanium(4+) Chemical compound [Ti+4].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-].CCCCCCCC[O-] KSCKTBJJRVPGKM-UHFFFAOYSA-N 0.000 description 1
- 229940073665 octyldodecyl myristate Drugs 0.000 description 1
- 229940049964 oleate Drugs 0.000 description 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 description 1
- 125000001117 oleyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])/C([H])=C([H])\C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 210000003463 organelle Anatomy 0.000 description 1
- 235000005985 organic acids Nutrition 0.000 description 1
- 239000003960 organic solvent Substances 0.000 description 1
- 235000006408 oxalic acid Nutrition 0.000 description 1
- 239000006201 parenteral dosage form Substances 0.000 description 1
- 230000037361 pathway Effects 0.000 description 1
- LCLHHZYHLXDRQG-ZNKJPWOQSA-N pectic acid Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)O[C@H](C(O)=O)[C@@H]1OC1[C@H](O)[C@@H](O)[C@@H](OC2[C@@H]([C@@H](O)[C@@H](O)[C@H](O2)C(O)=O)O)[C@@H](C(O)=O)O1 LCLHHZYHLXDRQG-ZNKJPWOQSA-N 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229960005323 phenoxyethanol Drugs 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 235000013550 pizza Nutrition 0.000 description 1
- 229920000435 poly(dimethylsiloxane) Polymers 0.000 description 1
- 229920001223 polyethylene glycol Polymers 0.000 description 1
- 239000010318 polygalacturonic acid Substances 0.000 description 1
- 239000001818 polyoxyethylene sorbitan monostearate Substances 0.000 description 1
- 235000010989 polyoxyethylene sorbitan monostearate Nutrition 0.000 description 1
- 229920001155 polypropylene Polymers 0.000 description 1
- 229920001282 polysaccharide Polymers 0.000 description 1
- 239000005017 polysaccharide Substances 0.000 description 1
- 150000004804 polysaccharides Chemical class 0.000 description 1
- 229940113124 polysorbate 60 Drugs 0.000 description 1
- 229940068965 polysorbates Drugs 0.000 description 1
- 229920002451 polyvinyl alcohol Polymers 0.000 description 1
- 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 1
- 239000001267 polyvinylpyrrolidone Substances 0.000 description 1
- 229920000036 polyvinylpyrrolidone Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000011591 potassium Substances 0.000 description 1
- 229960003975 potassium Drugs 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- GNSKLFRGEWLPPA-UHFFFAOYSA-M potassium dihydrogen phosphate Chemical compound [K+].OP(O)([O-])=O GNSKLFRGEWLPPA-UHFFFAOYSA-M 0.000 description 1
- 159000000001 potassium salts Chemical class 0.000 description 1
- 230000001376 precipitating effect Effects 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- SXBRULKJHUOQCD-UHFFFAOYSA-N propanoic acid Chemical compound CCC(O)=O.CCC(O)=O SXBRULKJHUOQCD-UHFFFAOYSA-N 0.000 description 1
- 239000004405 propyl p-hydroxybenzoate Substances 0.000 description 1
- 235000010232 propyl p-hydroxybenzoate Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- RADKZDMFGJYCBB-UHFFFAOYSA-N pyridoxal hydrochloride Natural products CC1=NC=C(CO)C(C=O)=C1O RADKZDMFGJYCBB-UHFFFAOYSA-N 0.000 description 1
- GHBFNMLVSPCDGN-UHFFFAOYSA-N rac-1-monooctanoylglycerol Chemical compound CCCCCCCC(=O)OCC(O)CO GHBFNMLVSPCDGN-UHFFFAOYSA-N 0.000 description 1
- 229960000342 retinol acetate Drugs 0.000 description 1
- QGNJRVVDBSJHIZ-QHLGVNSISA-N retinyl acetate Chemical compound CC(=O)OC\C=C(/C)\C=C\C=C(/C)\C=C\C1=C(C)CCCC1(C)C QGNJRVVDBSJHIZ-QHLGVNSISA-N 0.000 description 1
- 235000019173 retinyl acetate Nutrition 0.000 description 1
- 239000011770 retinyl acetate Substances 0.000 description 1
- 229960002477 riboflavin Drugs 0.000 description 1
- 235000009566 rice Nutrition 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- HFHDHCJBZVLPGP-UHFFFAOYSA-N schardinger α-dextrin Chemical compound O1C(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC(C(O)C2O)C(CO)OC2OC(C(C2O)O)C(CO)OC2OC2C(O)C(O)C1OC2CO HFHDHCJBZVLPGP-UHFFFAOYSA-N 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 210000002966 serum Anatomy 0.000 description 1
- 229920002545 silicone oil Polymers 0.000 description 1
- 229910001961 silver nitrate Inorganic materials 0.000 description 1
- 230000037380 skin damage Effects 0.000 description 1
- 235000011888 snacks Nutrition 0.000 description 1
- WXMKPNITSTVMEF-UHFFFAOYSA-M sodium benzoate Chemical compound [Na+].[O-]C(=O)C1=CC=CC=C1 WXMKPNITSTVMEF-UHFFFAOYSA-M 0.000 description 1
- 239000004299 sodium benzoate Substances 0.000 description 1
- 235000010234 sodium benzoate Nutrition 0.000 description 1
- 239000011780 sodium chloride Substances 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- NLJMYIDDQXHKNR-UHFFFAOYSA-K sodium citrate Chemical compound O.O.[Na+].[Na+].[Na+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O NLJMYIDDQXHKNR-UHFFFAOYSA-K 0.000 description 1
- 229940010747 sodium hyaluronate Drugs 0.000 description 1
- 229940074404 sodium succinate Drugs 0.000 description 1
- ZDQYSKICYIVCPN-UHFFFAOYSA-L sodium succinate (anhydrous) Chemical compound [Na+].[Na+].[O-]C(=O)CCC([O-])=O ZDQYSKICYIVCPN-UHFFFAOYSA-L 0.000 description 1
- YWIVKILSMZOHHF-QJZPQSOGSA-N sodium;(2s,3s,4s,5r,6r)-6-[(2s,3r,4r,5s,6r)-3-acetamido-2-[(2s,3s,4r,5r,6r)-6-[(2r,3r,4r,5s,6r)-3-acetamido-2,5-dihydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-2-carboxy-4,5-dihydroxyoxan-3-yl]oxy-5-hydroxy-6-(hydroxymethyl)oxan-4-yl]oxy-3,4,5-trihydroxyoxane-2- Chemical compound [Na+].CC(=O)N[C@H]1[C@H](O)O[C@H](CO)[C@@H](O)[C@@H]1O[C@H]1[C@H](O)[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](O[C@H]3[C@@H]([C@@H](O)[C@H](O)[C@H](O3)C(O)=O)O)[C@H](O)[C@@H](CO)O2)NC(C)=O)[C@@H](C(O)=O)O1 YWIVKILSMZOHHF-QJZPQSOGSA-N 0.000 description 1
- GGCZERPQGJTIQP-UHFFFAOYSA-N sodium;9,10-dioxoanthracene-2-sulfonic acid Chemical compound [Na+].C1=CC=C2C(=O)C3=CC(S(=O)(=O)O)=CC=C3C(=O)C2=C1 GGCZERPQGJTIQP-UHFFFAOYSA-N 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 229950004959 sorbitan oleate Drugs 0.000 description 1
- 235000014347 soups Nutrition 0.000 description 1
- 235000020712 soy bean extract Nutrition 0.000 description 1
- 229940032094 squalane Drugs 0.000 description 1
- 239000008117 stearic acid Substances 0.000 description 1
- 239000008227 sterile water for injection Substances 0.000 description 1
- 230000001954 sterilising effect Effects 0.000 description 1
- 238000004659 sterilization and disinfection Methods 0.000 description 1
- 238000003756 stirring Methods 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-L succinate(2-) Chemical compound [O-]C(=O)CCC([O-])=O KDYFGRWQOYBRFD-UHFFFAOYSA-L 0.000 description 1
- 235000000346 sugar Nutrition 0.000 description 1
- 150000005846 sugar alcohols Chemical class 0.000 description 1
- 150000008163 sugars Chemical class 0.000 description 1
- 235000020238 sunflower seed Nutrition 0.000 description 1
- 230000000475 sunscreen effect Effects 0.000 description 1
- 239000000516 sunscreening agent Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 239000003765 sweetening agent Substances 0.000 description 1
- 239000006188 syrup Substances 0.000 description 1
- 235000020357 syrup Nutrition 0.000 description 1
- 229940095064 tartrate Drugs 0.000 description 1
- 229960003080 taurine Drugs 0.000 description 1
- 235000013616 tea Nutrition 0.000 description 1
- 229960003495 thiamine Drugs 0.000 description 1
- DPJRMOMPQZCRJU-UHFFFAOYSA-M thiamine hydrochloride Chemical compound Cl.[Cl-].CC1=C(CCO)SC=[N+]1CC1=CN=C(C)N=C1N DPJRMOMPQZCRJU-UHFFFAOYSA-M 0.000 description 1
- 239000006211 transdermal dosage form Substances 0.000 description 1
- QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
- LWIHDJKSTIGBAC-UHFFFAOYSA-K tripotassium phosphate Chemical compound [K+].[K+].[K+].[O-]P([O-])([O-])=O LWIHDJKSTIGBAC-UHFFFAOYSA-K 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 230000000007 visual effect Effects 0.000 description 1
- NCYCYZXNIZJOKI-UHFFFAOYSA-N vitamin A aldehyde Natural products O=CC=C(C)C=CC=C(C)C=CC1=C(C)CCCC1(C)C NCYCYZXNIZJOKI-UHFFFAOYSA-N 0.000 description 1
- 235000010374 vitamin B1 Nutrition 0.000 description 1
- 239000011691 vitamin B1 Substances 0.000 description 1
- 235000019163 vitamin B12 Nutrition 0.000 description 1
- 239000011715 vitamin B12 Substances 0.000 description 1
- 235000019164 vitamin B2 Nutrition 0.000 description 1
- 239000011716 vitamin B2 Substances 0.000 description 1
- 235000019158 vitamin B6 Nutrition 0.000 description 1
- 239000011726 vitamin B6 Substances 0.000 description 1
- 235000019165 vitamin E Nutrition 0.000 description 1
- 239000011709 vitamin E Substances 0.000 description 1
- 229940046009 vitamin E Drugs 0.000 description 1
- 229940011671 vitamin b6 Drugs 0.000 description 1
- 238000005406 washing Methods 0.000 description 1
- 239000000230 xanthan gum Substances 0.000 description 1
- 229920001285 xanthan gum Polymers 0.000 description 1
- 235000010493 xanthan gum Nutrition 0.000 description 1
- 229940082509 xanthan gum Drugs 0.000 description 1
- 239000011787 zinc oxide Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/31—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/01—Hydrocarbons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/02—Preparations for care of the skin for chemically bleaching or whitening the skin
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2200/00—Function of food ingredients
- A23V2200/30—Foods, ingredients or supplements having a functional effect on health
- A23V2200/318—Foods, ingredients or supplements having a functional effect on health having an effect on skin health and hair or coat
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2250/00—Food ingredients
- A23V2250/30—Other Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Epidemiology (AREA)
- Polymers & Plastics (AREA)
- Food Science & Technology (AREA)
- Nutrition Science (AREA)
- Mycology (AREA)
- Birds (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cosmetics (AREA)
Abstract
Description
본 발명은 옥타데센(octadecene) 또는 이의 염을 유효성분으로 포함하는 피부 미백 조성물에 관한 것으로, 보다 상세하게는 옥타데센(octadecene) 또는 이의 염을 유효성분으로 포함함으로써 우수한 멜라닌 생성 억제 효과를 구현할 수 있는 피부 미백용 조성물에 관한 것이다.The present invention relates to a skin whitening composition comprising an octadecene or a salt thereof as an active ingredient, and more particularly, to include an octadecene or a salt thereof as an active ingredient, thereby providing an excellent melanin suppression effect. The present invention relates to a skin whitening composition.
사람의 피부색은 멜라닌, 카로틴 및 헤모글로빈의 양에 따라 결정되는데 이중에서도 멜라닌이 피부색을 결정하는 주요인자로 작용한다. 멜라닌은 피부 표피층(epidermis)에 존재하는 멜라닌세포(melanocyte)에서 생성된 후 주변의 각질형성 세포(keratinocyte)로 전이(migration)되어 피부색을 나타내는 것으로 알려져 있다. 이외에도 멜라닌은 자외선에 의한 피부 손상을 막고 활성산소(reactive oxygen species, ROS)를 제거하여 피부를 보호하는 역할을 한다. 그러나 만성적인 자외선 노출은 멜라닌세포(melanocyte)에서 멜라닌 생성을 촉진시켜 색소침착(pigmentation)을 유발하는 것으로 알려져 있다. Human skin color is determined by the amount of melanin, carotene and hemoglobin, of which melanin is a major factor in determining skin color. Melanin is known to be produced in melanocytes (melanocyte) present in the epidermis of the skin and then migrated to surrounding keratinocytes to show skin color. In addition, melanin protects the skin by preventing skin damage caused by ultraviolet rays and removing reactive oxygen species (ROS). However, chronic UV exposure is known to promote melanogenesis in melanocytes and cause pigmentation.
멜라닌 생성은 멜라닌세포 내의 멜라노좀(melanosome)에서 개시된다. 피부가 자외선과 같은 외부 스트레스에 노출되면 멜라닌세포에서 α-MSH(α-melanocyte stimulating hormone)의 생성량이 증가하고, α-MSH는 멜라닌세포에서만 발현되는 막 수용체인 MC1R(melanocortin 1 receptor)과 결합하여 아데닐일 사이클라제(adenylyl cyclase)를 활성화시켜 세포 내 cAMP(cyclic adenosine monophosphate)를 증폭시키는 것으로 알려져 있다. 세포 내 cAMP 수준이 증가하면 PKA(protein kinase A)가 활성화됨에 따라 CREB(cAMP response element binding protein)가 인산화되고, 결과적으로 MITF (microphthalmia transcription factor)의 발현이 증가된다. MITF는 멜라닌 합성과정의 중요 전사인자로서 멜라닌 합성의 주요 효소인 티로시나아제의 수준을 증가시키며, 티로시나아제는 멜라닌 합성의 초기단계에 작용하여 멜라닌 합성의 속도를 조절하는 것으로 잘 알려져 있다. 이러한 경로로 멜라닌 세포에서의 멜라닌 합성은 MITF, 티로시나아제 등의 효소가 관여하는 복잡한 과정을 통해 이루어진다.Melanogenesis is initiated in melanosomes in melanocytes. When the skin is exposed to external stress such as ultraviolet rays, the production of α-melanocyte stimulating hormone (α-MSH) increases in melanocytes, and α-MSH binds to the melanocortin 1 receptor (MC1R), a membrane receptor expressed only in melanocytes. It is known to amplify intracellular cAMP (cyclic adenosine monophosphate) by activating adenylyl cyclase. As intracellular cAMP levels are increased, protein kinase A (PKA) is activated, which leads to phosphorylation of cAMP response element binding protein (CREB), resulting in increased expression of MITF (microphthalmia transcription factor). MITF is an important transcription factor in melanin synthesis and increases the level of tyrosinase, a major enzyme in melanin synthesis. Tyrosinase is well known to regulate the rate of melanin synthesis by acting at the early stage of melanin synthesis. With this pathway, melanin synthesis in melanocytes is a complex process involving enzymes such as MITF and tyrosinase.
본 발명자는, 피부 미백 효과가 우수한 물질에 대한 연구을 진행한 결과, 옥타데센(Octadecene) 또는 이의 염의 멜라닌 생성 억제 효과가 우수하다는 것을 확인하고 본 발명을 완성하였다.The present inventors conducted a study on a substance having an excellent skin whitening effect, and confirmed that octadecene (Octadecene) or its salt has an excellent melanin production inhibitory effect and completed the present invention.
본 발명의 목적은 옥타데센(octadecene) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 미백용 화장료 조성물을 제공하는 것이다.It is an object of the present invention to provide a cosmetic composition for skin whitening comprising octadecene or a cosmetically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 목적은 옥타데센(octadecene) 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 미백용 건강기능식품 조성물에 관한 것이다.Another object of the present invention relates to a health functional food composition for skin whitening comprising octadecene or a food acceptable salt thereof as an active ingredient.
본 발명의 또 다른 목적은 옥타데센(octadecene) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 색소 침착의 예방 또는 치료용 약학적 조성물에 관한 것이다.Another object of the present invention relates to a pharmaceutical composition for preventing or treating skin pigmentation, comprising octadecene or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 또 다른 목적은 옥타데센(octadecene) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 색소 침착의 예방 또는 개선용 의약외품 조성물에 관한 것이다.Another object of the present invention relates to a quasi-drug composition for the prevention or improvement of skin pigmentation comprising octadecene or a pharmaceutically acceptable salt thereof as an active ingredient.
그러나, 본 발명이 이루고자 하는 기술적 과제는 이상에서 언급한 과제에 제한되지 않으며, 언급되지 않은 또 다른 과제들은 아래의 기재로부터 당업자에게 명확하게 이해될 수 있을 것이다.However, the technical problem to be achieved by the present invention is not limited to the above-mentioned problem, another task that is not mentioned will be clearly understood by those skilled in the art from the following description.
본 발명은, 옥타데센(octadecene) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 미백용 화장료 조성물을 제공한다.The present invention provides a cosmetic composition for skin whitening comprising octadecene or a cosmetically acceptable salt thereof as an active ingredient.
상기 유효성분은 MITF(microphthalmia transcription factor) 또는 티로시나아제의 발현을 억제할 수 있다. The active ingredient may inhibit the expression of a microphthalmia transcription factor (MITF) or tyrosinase.
상기 유효성분은 멜라닌 세포 자극 호르몬 (Melanocyte-Stimulating Hormone, α-MSH)에 의해 유도되는 멜라닌 생성을 억제할 수 있다. The active ingredient may inhibit melanin production induced by melanocyte-stimulating hormone (α-MSH).
상기 조성물은 스킨로션, 스킨 소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스처 로션, 영양로션, 맛사지 크림, 영양크림, 모이스처 크림, 핸드크림, 에센스, 팩, 마스크팩, 마스크시트, 각질제거제, 비누, 샴푸, 클렌징 폼, 클렌징로션, 클렌징크림, 바디로션, 바디클렌저, 유액, 프레스파우더, 루스파우더 및 아이섀도로 이루어진 군에서 선택되는 어느 하나의 제형으로 제조될 수 있다.The composition includes skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisturizing cream, hand cream, essence, pack, mask pack, mask sheet, exfoliant, Soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, emulsion, press powder, loose powder and eye shadow can be prepared in any one of the formulations selected from the group consisting of.
상기 유효성분은 화장료 조성물 전체 중량에 대하여 0.0001 내지 20 중량%로 포함될 수 있다. The active ingredient may be included in an amount of 0.0001 to 20% by weight based on the total weight of the cosmetic composition.
또한, 본 발명은 옥타데센(octadecene) 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 미백용 건강기능식품 조성물을 제공한다.In addition, the present invention provides a health functional food composition for skin whitening comprising octadecene or a pharmaceutically acceptable salt thereof as an active ingredient.
상기 조성물은 정제, 과립, 분말, 캅셀, 액상의 용액 및 환으로 이루어진 군에서 선택되는 어느 하나의 제형으로 제조될 수 있다. The composition may be prepared in any one formulation selected from the group consisting of tablets, granules, powders, capsules, liquid solutions and rings.
또한, 본 발명은 옥타데센(octadecene) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 색소 침착의 예방 또는 치료용 약학적 조성물을 제공한다. The present invention also provides a pharmaceutical composition for the prevention or treatment of skin pigmentation comprising octadecene or a pharmaceutically acceptable salt thereof as an active ingredient.
또한, 본 발명은, 옥타데센(octadecene) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 색소 침착의 예방 또는 개선용 의약외품 조성물을 제공한다. The present invention also provides a quasi-drug composition for the prevention or improvement of skin pigmentation comprising octadecene or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명에 따른, 옥타데센(octadecene) 또는 이의 염을 유효성분으로 포함하는 조성물은 멜라닌 세포 자극 호르몬 (Melanocyte-Stimulating Hormone, αMSH)에 의해 유도되는 멜라닌 생성 억제 효과가 우수하고, 인체에 안전하며 부작용이 적어 화장품, 건강기능식품, 의약품 또는 의약외품 등의 소재로 다양하게 사용될 수 있다.According to the present invention, a composition containing octadecene or a salt thereof as an active ingredient is excellent in inhibiting melanin production induced by melanocyte-Stimulating Hormone (αMSH), safe to human body and side effects. This can be used in a variety of materials, such as cosmetics, health food, medicine or quasi-drugs.
도 1은 옥타데센을 처리한 B6F10 멜라닌세포의 펠릿(pellet)색 변화를 분석한 결과를 나타내는 것이다.
도 2는 옥타데센을 처리한 B6F10 멜라닌세포의 멜라닌 생성량 변화를 나타내는 그래프이다 (각 값은 3 회의 평균 ± SEM 임)[일원분산분석(one-way ANOVA)].
도 3은 옥타데센을 처리한 B6F10 멜라닌세포의 유전자 발현 변화를 나타내는 그래프이다(각 값은3 회의 평균 ± SEM 임; 막대 위의 글자는 P<0.05에서 통계적 유의적 차이를 나타낸 것임)[일원분산분석(one-way ANOVA)].
Figure 1 shows the results of analyzing the pellet (pellet) color change of B6F10 melanocytes treated with octadecene.
Figure 2 is a graph showing the change in melanin production of octadecene-treated B6F10 melanocytes (each value is three times ± SEM) (one-way ANOVA).
Figure 3 is a graph showing the change in gene expression of B6F10 melanocytes treated with octadecene (each value is the mean ± SEM three times; the letters on the bar shows a statistically significant difference at P <0.05) Analysis (one-way ANOVA)].
본 발명자는 옥타데센(Octadecene) 또는 이의 염이 현저하게 우수한 미백 효과를 나타내는 것을 확인하고, 본 발명을 완성하였다. The present inventors have confirmed that octadecene or salts thereof have a remarkably excellent whitening effect, and completed the present invention.
이하 본 발명을 상세히 설명한다. Hereinafter, the present invention will be described in detail.
본 발명은 옥타데센(octadecene) 또는 이의 염을 유효성분으로 포함하는 피부 미백용 조성물을 제공한다.The present invention provides a composition for skin whitening comprising octadecene or a salt thereof as an active ingredient.
상기 유효성분은 MITF(microphthalmia transcription factor) 또는 티로시나아제의 발현을 억제할 수 있다. 또한 상기 유효성분은 멜라닌 세포 자극 호르몬 (Melanocyte-Stimulating Hormone, αMSH)에 의해 유도되는 멜라닌 생성을 억제할 수 있다. The active ingredient may inhibit the expression of a microphthalmia transcription factor (MITF) or tyrosinase. In addition, the active ingredient can inhibit the production of melanin induced by melanocyte stimulating hormone (Melanocyte-Stimulating Hormone, αMSH).
옥타데센(Octadecene)은 알켄(alkene)계 화합물이다. 옥타데센의 화학식은 C18H36이고 분자량은 252.5 g/mol이며, 구조는 아래 화학식 1과 같다. 옥타데센은 투명한 고체이며, 알코올, 아세톤 등에는 잘 용해되며, 물에는 잘 녹지 않는다. 옥타데센은 주로 윤활제, 광택보조제 등으로 상업적으로 이용되고 있다. 그러나 현재까지 옥타데센의 미백 효능은 알려진 바 없다. Octadecene is an alkene-based compound. Octadecene has a chemical formula of C 18 H 36 , a molecular weight of 252.5 g / mol, and a structure thereof. Octadecene is a transparent solid, soluble in alcohol, acetone, etc., and insoluble in water. Octadecene is mainly used commercially as a lubricant, a gloss aid, and the like. However, the whitening efficacy of octadecene has not been known to date.
[화학식 1] 옥타데센(octadecene)의 분자구조[Formula 1] Molecular structure of octadecene
본 발명의 옥타데센(octadecene)의 수득 방법은 특별히 한정되지 않으며, 천연물에서 분리하거나, 공지된 제법을 사용하여 화학적으로 합성하거나, 시판되는 것을 사용할 수 있다.The method for obtaining octadecene of the present invention is not particularly limited, and may be isolated from natural products, chemically synthesized using a known manufacturing method, or commercially available.
본 발명에서, 상기 옥타데센(octadecene)은 이와 동일한 효능을 갖는 범위 내에서 옥타데센(octadecene) 수화물, 옥타데센(octadecene) 유도체 등을 포함할 수 있으며, 이의 용매화합물이나 입체 이성질체를 포함할 수 있다.In the present invention, the octadecene (octadecene) may include octadecene hydrate, octadecene derivatives, etc. within the range having the same efficacy, and may include a solvate or stereoisomer thereof. .
본 발명에서, 용어 "피부 미백"은 멜라닌 색소의 합성을 저해함으로써 피부 톤을 맑게 할 뿐만 아니라, 자외선, 호르몬 또는 유전에 기인한 기미나 주근깨 등의 피부 과색소 침착을 개선하는 것을 의미한다.In the present invention, the term "skin whitening" means not only to clear skin tone by inhibiting the synthesis of melanin pigments, but also to improve skin hyperpigmentation such as blemishes and freckles due to ultraviolet rays, hormones or heredity.
본 발명에서, 용어 "화장품학적으로 허용 가능한 염", "식품학적으로 허용 가능한 염", "약학적으로 허용 가능한 염" 또는 "이의 염"은 옥타데센(octadecene)이 다른 물질과 결합한 염의 형태인 것으로, 옥타데센과 유사한 활성을 나타낼 수 있는 물질을 의미할 수 있다. 상기 "화장품학적으로 허용 가능한 염", "식품학적으로 허용 가능한 염", "약학적으로 허용 가능한 염" 또는 "이의 염"은 유리산(free acid)에 의해 형성된 산 부가염일 수 있다. 산 부가염은 통상의 방법, 예를 들어 화합물을 과량의 산 수용액에 용해시키고, 이 염을 수혼화성 유기 용매, 예를 들어 메탄올, 에탄올, 아세톤 또는 아세토니트릴을 사용하여 침전시켜서 제조할 수 있다. 또한, 동 몰량의 화합물 및 물 중의 산 또는 알코올 (예를 들어, 글리콜 모노메틸 에테르)을 가열하고, 이어서 상기 혼합물을 증발시켜 건조시키거나, 또는 석출된 염을 흡인 여과시킬 수 있다.In the present invention, the term “cosmetic acceptable salt”, “food acceptable salt”, “pharmaceutically acceptable salt” or “salt thereof” is in the form of a salt in which octadecene is combined with another substance. As such, it may mean a material capable of exhibiting similar activity to octadecene. The "cosmetic acceptable salt", "food acceptable salt", "pharmaceutically acceptable salt" or "salt thereof" may be an acid addition salt formed by free acid. Acid addition salts can be prepared by conventional methods, for example by dissolving a compound in an excess of aqueous acid solution and precipitating the salt using a water miscible organic solvent, such as methanol, ethanol, acetone or acetonitrile. In addition, the same molar amount of the compound and the acid or alcohol (eg, glycol monomethyl ether) in water can be heated and the mixture can then be evaporated to dryness or the precipitated salts can be suction filtered.
상기 유리산으로는 무기산 또는 유기산을 사용할 수 있다. 상기 무기산의 비제한적인 예로는 염산, 인산, 황산, 질산, 주석산 등을 사용할 수 있으며, 이들은 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다. 상기 유기산의 비제한적인 예로는 메탄술폰산, p-톨루엔술폰산, 아세트산, 트리플루오로아세트산, 말레인산 (maleic acid), 숙신산, 옥살산, 벤조산, 타르타르산, 푸마르산 (fumaric acid), 만데르산, 프로피온산 (propionic acid), 구연산 (citric acid), 젖산 (lactic acid), 글리콜산 (glycollic acid), 글루콘산 (gluconic acid), 갈락투론산 (galacturonic acid), 글루탐산, 글루타르산 (glutaric acid), 글루쿠론산 (glucuronic acid), 아스파르트산, 아스코르브산, 카본산, 바닐릭산, 하이드로아이오딕산 등을 사용할 수 있다. 이들은 단독으로 사용되거나 2 종 이상을 혼합하여 사용될 수 있다.As the free acid, an inorganic acid or an organic acid may be used. Non-limiting examples of the inorganic acid may be hydrochloric acid, phosphoric acid, sulfuric acid, nitric acid, tartaric acid, and the like, which may be used alone or in combination of two or more. Non-limiting examples of the organic acid are methanesulfonic acid, p-toluenesulfonic acid, acetic acid, trifluoroacetic acid, maleic acid, succinic acid, oxalic acid, benzoic acid, tartaric acid, fumaric acid, manderic acid, propionic acid (propionic acid) acid, citric acid, lactic acid, glycolic acid, gluconic acid, galacturonic acid, glutamic acid, glutaric acid, glucuronic acid (glucuronic acid), aspartic acid, ascorbic acid, carbonic acid, vanic acid, hydroiodic acid and the like can be used. These may be used alone or in combination of two or more thereof.
또한, 상기 옥타데센(octadecene)은 염기를 사용하여 화장품학적으로 또는 식품학적으로 허용 가능한 금속염을 만들 수 있다. 알칼리 금속 또는 알칼리 토금속 염은, 예를 들어 화합물을 과량의 알칼리 금속 수산화물 또는 알칼리 토금속 수산화물 용액 중에 용해시키고, 비용해 화합물 염을 여과한 후 여액을 증발, 건조시켜 얻을 수 있다. 상기 금속염으로는 특히 나트륨, 칼륨 또는 칼슘염을 제조하는 것이 바람직하나 이들에 제한되는 것은 아니다. 또한, 이에 대응하는 은염은 알칼리 금속 또는 알칼리 토금속 염을 적당한 은염 (예를 들어, 질산은)과 반응시켜 얻을 수 있다.In addition, the octadecene (octadecene) can be used to make a cosmetically or food acceptable metal salt using a base. Alkali metal or alkaline earth metal salts can be obtained, for example, by dissolving the compound in an excess of alkali metal hydroxide or alkaline earth metal hydroxide solution, filtering the insoluble compound salt, and then evaporating and drying the filtrate. As the metal salt, it is particularly preferable to prepare sodium, potassium or calcium salts, but is not limited thereto. Corresponding silver salts can also be obtained by reacting an alkali metal or alkaline earth metal salt with a suitable silver salt (eg silver nitrate).
상기 옥타데센의 염은, 달리 지시되지 않는 한, 상기 옥타데센의 화합물에 존재할 수 있는 산성 또는 염기성 기의 염을 모두 포함할 수 있다. 예를 들어 상기 옥타데센의 염으로는 하이드록시기의 나트륨, 칼슘 및 칼륨염 등이 포함될 수 있고, 아미노기의 기타 화장품학적으로 허용 가능한 염으로는 하드로브로마이드, 황산염, 수소 황산염, 인산염, 수소 인산염, 이수소 인산염, 아세테이트, 숙시네이트, 시트레이트, 타르트레이트, 락테이트, 만델레이트, 메탄술포네이트 (메실레이트) 및 p-톨루엔술포네이트 (토실레이트)염 등을 들 수 있으며 당업계에서 알려진 염의 제조 방법을 통하여 제조될 수 있다.The salts of octadecene may include all salts of acidic or basic groups which may be present in the compound of octadecene, unless otherwise indicated. For example, the salt of the octadecene may include sodium, calcium and potassium salts of the hydroxy group, and other cosmetically acceptable salts of the amino group include hardbromide, sulfate, hydrogen sulfate, phosphate, hydrogen phosphate , Dihydrogen phosphate, acetate, succinate, citrate, tartrate, lactate, mandelate, methanesulfonate (mesylate) and p-toluenesulfonate (tosylate) salts and the like. It may be prepared through a manufacturing method.
본 발명은, 옥타데센(octadecene) 또는 이의 화장품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 미백용 화장료 조성물을 제공한다. The present invention provides a cosmetic composition for skin whitening comprising octadecene or a cosmetically acceptable salt thereof as an active ingredient.
본 발명의 화장료 조성물에서 상기 유효성분의 유효 함량은 특별히 제한되지 않으며, 조성물 전체 중량에 대하여 0.0001 내지 20 중량%로 포함되는 것일 수 있다. 상기 유효성분이 화장료 조성물 내에 0.0001 중량% 미만인 경우에는 그 용량이 소량이어서 기대하는 미백 개선 효과가 없을 수 있으며, 20 중량%를 초과하는 경우 효과의 변화가 미미하거나 기존에 알려진 독성을 나타낼 가능성이 있다.The effective amount of the active ingredient in the cosmetic composition of the present invention is not particularly limited and may be included in 0.0001 to 20% by weight based on the total weight of the composition. When the active ingredient is less than 0.0001% by weight in the cosmetic composition may have a small amount of the whitening effect is not expected, if the amount exceeds 20% by weight, the effect of the change is small or there is a possibility of exhibiting known toxicity.
본 발명에서 사용되는 용어, "화장료 조성물"은 상기 화합물을 포함하는 조성물로서 그 제형은 어떠한 형태라도 가능하다. 이러한 제형의 예를 들면 상기 조성물을 이용하여 제조된 화장료는 영양크림, 아이크림, 마사지크림, 클렌징 크림과 같은 크림류, 팩류, 영양로션과 같은 로션류, 에센스류, 유연화장수, 영양 화장수와 같은 화장수류, 파우더류, 파운데이션류 및 메이크업 베이스류 등이고, 본 발명의 목적을 달성하기 위하여 이러한 제형 중 어떠한 형태로도 제조되어 상용화될 수 있으며, 상기 예들에 한정되지 않는다. 또한, 본 발명에 따른 화장료 조성물에는 통상의 화장료 제조 방법으로 제형화할 수 있다.As used herein, the term "cosmetic composition" is a composition comprising the compound, the formulation may be in any form. Examples of such formulations include cosmetics prepared using the composition, such as nutrition creams, eye creams, massage creams, creams such as cleansing creams, packs, lotions such as nutrient lotions, essences, softeners, and nourishing lotions. And powders, foundations, makeup bases, and the like, and may be prepared and commercialized in any of these formulations to achieve the object of the present invention, and are not limited to the above examples. In addition, the cosmetic composition according to the present invention can be formulated by a conventional cosmetic preparation method.
구체적으로 본 발명의 화장료는 스킨로션, 스킨 소프너, 스킨토너, 아스트린젠트, 로션, 밀크로션, 모이스처 로션, 영양로션, 맛사지 크림, 영양크림, 모이스처 크림, 핸드크림, 에센스, 팩, 마스크팩, 마스크시트, 각질제거제, 비누, 샴푸, 클렌징 폼, 클렌징로션, 클렌징크림, 바디로션, 바디클렌저, 유액, 프레스파우더, 루스파우더 및 아이섀도로 이루어진 군에서 선택되는 어느 하나의 제형으로 제조될 수 있다.Specifically, the cosmetics of the present invention include skin lotion, skin softener, skin toner, astringent, lotion, milk lotion, moisturizing lotion, nutrition lotion, massage cream, nutrition cream, moisture cream, hand cream, essence, pack, mask pack, mask sheet , Exfoliant, soap, shampoo, cleansing foam, cleansing lotion, cleansing cream, body lotion, body cleanser, emulsion, press powder, loose powder and eye shadow can be prepared in any one of the formulations selected from the group consisting of.
본 발명의 화장료 조성물은 상기 유효성분(옥타데센 또는 이의 염)에 더하여 부형제, 담체 등 기타 첨가제를 포함할 수 있으며, 일반 피부 화장료에 배합되는 보통의 성분을 필요한 만큼 적용 배합하는 것이 가능하다.The cosmetic composition of the present invention may include other additives such as excipients, carriers, etc., in addition to the active ingredient (octadecene or salts thereof), and it is possible to apply and blend as needed the usual ingredients to be used in general skin cosmetics.
구체적으로, 본 발명의 화장료 조성물은 경피 침투 강화제를 추가로 포함할 수 있다. 본 발명에서 사용되는 용어, 경피 침투 강화제란 피부의 혈관세포 내로 원하는 성분이 높은 흡수율로 침투할 수 있게 해주는 조성물이다. 바람직하게는 레시틴 화장품에 사용되는 다른 인지질 성분, 리포좀 성분 등이 포함되지만 이에 국한되지는 않는다.Specifically, the cosmetic composition of the present invention may further include a transdermal penetration enhancer. As used herein, the term transdermal penetration enhancer is a composition that allows a desired component to penetrate into blood vessel cells of the skin at a high absorption rate. Preferably other phospholipid components, liposome components and the like used in lecithin cosmetics are included, but are not limited thereto.
또한, 유상 성분으로서 주로 사용될 수 있는 오일로는 식물성 오일, 광물성 오일, 실리콘유 및 합성유 중에서 선택된 하나 이상을 사용할 수 있다. 보다 구체적으로, 미네랄오일, 사이크로메치콘, 스쿠알란, 옥틸도데실 미리스테이트, 올리브 오일, 비티스 비니페라 씨드 오일, 마카다미아너트오일, 글리세릴옥타노에이트, 캐스터 오일, 에칠헥실 이소노나노에이트, 디메치콘, 사이크로펜타실록산 및 선플라워 씨드 오일 등을 사용할 수 있다.In addition, as the oil which can be mainly used as an oil phase component, one or more selected from vegetable oil, mineral oil, silicone oil and synthetic oil can be used. More specifically, mineral oil, cyclomethicone, squalane, octyldodecyl myristate, olive oil, Vitis binifera seed oil, macadamia nut oil, glyceryl octanoate, castor oil, ethylhexyl isononanoate, dimethicone Chicon, cyclopentasiloxane, sunflower seed oil and the like can be used.
또한, 유화 능력을 보강하기 위하여 계면활성제, 고급 알콜 등을 0.1 내지 5 중량% 첨가할 수 있다. 이러한 계면 활성제로는 비이온 계면활성제, 음이온성 계면 활성제, 양이온성 계면 활성제, 양성 계면 활성제, 인지질 등과 같은 통상적인 계면활성제를 사용할 수 있으며, 구체적으로, 소르비탄세스퀴놀리에이트, 폴리솔베이트 60, 글리세릴 스테아레이트, 친유형 글리세릴스테아레이트, 소르비탄 올리에이트, 소르비탄 스테아레이트, 디이에이-세틸포스페이트, 소르비탄스테아레이트/슈크로스코코에이트, 글리세릴스테아레이트/폴리에틸렌글라이콜-100 스테아레이트, 세테아레스-6 올리베이트, 아라키딜알코올/베헤닐알코올/아라키딜 글루코사이드, 폴리프로필렌글라이콜-26-부테스-26/폴리에틸렌글라이콜-40 하이드로제네이티드 캐스터오일 등을 사용할 수 있다. 고급 알콜로는 탄소수가 12 내지 20인 알코올, 예컨대 세틸알코올, 스테아릴 알코올, 옥틸도데칸올, 이소스테아릴 알코올 등을 단독으로 또는 1종 이상 혼합하여 사용할 수 있다.In addition, 0.1 to 5% by weight of a surfactant, a higher alcohol, and the like may be added to reinforce the emulsifying ability. Such surfactants may be used conventional surfactants such as nonionic surfactants, anionic surfactants, cationic surfactants, amphoteric surfactants, phospholipids, and the like, specifically, sorbitan sesquinolate, polysorbate 60 , Glyceryl stearate, lipophilic glyceryl stearate, sorbitan oleate, sorbitan stearate, die-cetyl phosphate, sorbitan stearate / sucrosecoate, glyceryl stearate / polyethylene glycol-100 Stearate, ceteareth-6 oleate, arachidyl alcohol / behenyl alcohol / arachidyl glucoside, polypropylene glycol-26-butes-26 / polyethylene glycol-40 hydrogenated castor oil, etc. have. As the higher alcohol, alcohols having 12 to 20 carbon atoms, such as cetyl alcohol, stearyl alcohol, octyldodecanol, isostearyl alcohol, etc. may be used alone or in combination of one or more thereof.
수상 성분은 수상의 점도 또는 경도를 조절하기 위하여 카보머, 잔탄검, 벤토나이트, 마그네슘알루미늄실리케이트, 셀룰로오스검, 덱스트린 팔미테이트 등과 같은 1종 이상의 점증제를 0.001 내지 5 중량% 더 첨가할 수 있다.The aqueous phase component may further add 0.001 to 5% by weight of one or more thickeners such as carbomer, xanthan gum, bentonite, magnesium aluminum silicate, cellulose gum, dextrin palmitate and the like to adjust the viscosity or hardness of the aqueous phase.
또한, 본 발명의 화장료 조성물에는 필요에 따라 고급 지방산, 비타민 등의 약효 성분과 자외선 차단제, 산화 방지제(부틸히드록시아니솔, 갈릭산프로필, 엘리소르빈산, 토코페릴아세테이드, 부틸레이티드하이드록시톨루엔 등), 방부제(메칠파라벤, 부틸파라벤, 프로필파라벤, 페녹시에탄올, 이미다졸리디닐우레아, 클로르페네신 등), 착색제, pH 조절제(트리에탄올아민, 씨트릭애씨드, 시트르산, 시트르산나트륨, 말산, 말산나트륨, 프말산, 프말산나트륨, 숙신산, 숙신산나트륨, 수산화나트륨, 인산일수소나트륨 등), 보습제(글리세린, 솔비톨, 프로필렌 글라이콜, 부틸렌 글라이콜, 헥실렌 글라이콜, 디글리세린, 베타인, 글리세레스-26, 메칠글루세스-20 등), 윤활제 등의 성분을 더 첨가할 수 있다.In addition, the cosmetic composition of the present invention, if necessary, active ingredients such as higher fatty acids, vitamins, sunscreens, antioxidants (butylhydroxyanisole, propyl gallic acid, elixolic acid, tocopheryl acetate, butylated hydroxy) Toluene, etc.), preservatives (methylparaben, butylparaben, propylparaben, phenoxyethanol, imidazolidinylurea, chlorphenesin, etc.), colorants, pH regulators (triethanolamine, citric acid, citric acid, sodium citrate, malic acid, Sodium malic acid, pmaric acid, sodium pramate, succinic acid, sodium succinate, sodium hydroxide, sodium monohydrogen phosphate, etc., moisturizers (glycerine, sorbitol, propylene glycol, butylene glycol, hexylene glycol, diglycerin , Betaine, glycerin-26, methylgluse-20 and the like), lubricants and the like can be further added.
또한, 본 발명의 화장료 조성물은 피부에 필수 영양소를 보조적으로 제공할 수 있는 물질을 추가로 포함하는데, 바람직하게는 천연향, 화장품향, 또는 한약재가 포함되지만 이들에 국한되지 않는 보조제를 함유할 수 있다.In addition, the cosmetic composition of the present invention further includes a substance capable of auxiliaryly providing essential nutrients to the skin, and may preferably contain auxiliary agents including, but not limited to, natural flavors, cosmetic flavors, or herbal medicines. have.
또한 본 발명은, 옥타데센(octadecene) 또는 이의 염을 유효성분으로 포함하는 피부 미백용 피부 외용제 조성물을 제공한다.The present invention also provides an external skin composition for skin whitening comprising octadecene or a salt thereof as an active ingredient.
본 발명의 용어 "피부 외용제"는 일반적으로 피부 외용에 사용하는 물질 전반을 포함하는 포괄하는 개념으로, 피부 외용제 제형의 비제한적인 예로는 경고제(PLASTERS), 로션제(LOTIONS), 리니멘트제(LINIMENTS), 액제(LIQUIDS AND SOLUTIONS), 에어로솔제(AEROSOLS), 엑스제(EXTRACTS), 연고제(OINTMENTS), 유동엑스제(FLUIDEXTRACTS), 유제(EMULSIONS), 현탁제(SUSPESIONS), 캅셀제(CAPSULES), 크림제(CREAMS), 연질, 경질 젤라틴 캅셀, 첩부제, 또는 서방화 제제 등이 있다.The term "skin external preparation" of the present invention is a general concept encompassing a substance generally used for external application of the skin, and non-limiting examples of the external preparation for skin include PLASTERS, LOTIONS, and lining agents. LIQUIDS AND SOLUTIONS, AEROSOLS, EXTRACTS, OINTMENTS, FLUIDEXTRACTS, Emulsions, SUPESIONS, CAPSULES , Creams (CREAMS), soft, hard gelatin capsules, patches, or sustained release preparations.
본 발명에 따른 피부 외용제는 상용되는 무기 또는 유기의 담체, 부형제 및 희석제를 가하여 고체, 반고체 또는 액상의 형태로 제제화된 비경구 투여제일 수 있다. 상기 비경구 투여를 위한 제재로는 점적제, 연고, 로션, 겔, 크림, 패취, 스프레이, 현탁제 및 유제로 이루어진 군에서 선택되는 경피 투여형 제형일 수 있으나, 이에 제한되지 않는다.The external preparation for skin according to the present invention may be a parenteral dosage form formulated in the form of a solid, semisolid or liquid by adding a commercially available inorganic or organic carrier, excipient and diluent. For parenteral administration, the preparation may be a transdermal dosage form selected from the group consisting of drops, ointments, lotions, gels, creams, patches, sprays, suspensions and emulsions, but is not limited thereto.
상기 외용제에 포함될 수 있는 담체, 부형제 및 희석제로는 락토즈, 덱스트로즈, 수크로스, 올리고당, 솔비톨, 만니톨, 자일리톨, 에리스리톨, 말티톨, 전분, 아카시아 고무, 알지네이트, 젤라틴, 칼슘 포스페이트, 칼슘 실리케이트, 셀룰로즈, 메틸 셀룰로즈, 미정질 셀룰로스, 폴리비닐 피롤리돈, 물, 메틸히드록시벤조에이트, 프로필히드록시벤조에이트, 탈크, 마그네슘 스테아레이트 및 광물유를 들 수 있다.Carriers, excipients and diluents that may be included in the external preparation include lactose, dextrose, sucrose, oligosaccharide, sorbitol, mannitol, xylitol, erythritol, maltitol, starch, acacia rubber, alginate, gelatin, calcium phosphate, calcium silicate, Cellulose, methyl cellulose, microcrystalline cellulose, polyvinyl pyrrolidone, water, methylhydroxybenzoate, propylhydroxybenzoate, talc, magnesium stearate and mineral oil.
본 발명의 옥타데센 또는 이의 염의 함량은 피부 외용제 조성물의 총 중량을 기준으로 각각 0.0001 내지 20 중량% 인 것이 바람직하다. 20 중량%를 초과하는 경우에는 조성물 제조 시 안정성 등이 떨어질 수 있고, 0.0001% 미만의 경우에는 그 작용효과가 미미하다.The content of the octadecene or salt thereof of the present invention is preferably 0.0001 to 20% by weight, respectively, based on the total weight of the skin external preparation composition. If it exceeds 20% by weight, the stability and the like during the preparation of the composition may be deteriorated, and if it is less than 0.0001%, its effect is insignificant.
각 제형에 의한 피부 외용제 조성물에 있어서, 상기한 본 발명의 조성물 이외의 다른 성분들을 기타 피부 외용제의 제형 또는 사용 목적 등에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있으며, 이 경우 다른 원료와 동시에 적용할 경우 상승효과가 일어날 수 있다.In the external preparation composition for skin by each formulation, other ingredients other than the composition of the present invention described above can be appropriately selected and blended by those skilled in the art according to the formulation or use purpose of the external preparation for skin, and in this case, simultaneously applied with other raw materials. If you do, synergistic effects may occur.
또한 본 발명은, 옥타데센(octadecene) 또는 이의 식품학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 미백용 건강기능식품 조성물을 제공한다.In another aspect, the present invention provides a health functional food composition for skin whitening comprising octadecene or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명에서 용어 "건강기능식품"은 인체에 유용한 기능성을 가진 원료나 성분을 사용하여 정제, 캅셀, 분말, 과립, 액상 및 환 등의 형태로 제조 및 가공한 식품을 말한다. 여기서 '기능성'이라 함은 인체의 구조 및 기능에 대하여 영양소를 조절하거나 생리학적 작용 등과 같은 보건용도에 유용한 효과를 얻는 것을 의미한다. 본 발명의 건강기능식품은 당 업계에서 통상적으로 사용되는 방법에 의하여 제조가능하며, 상기 제조 시에는 당 업계에서 통상적으로 첨가하는 원료 및 성분을 첨가하여 제조할 수 있다. 또한 상기 건강기능식품의 제형 또한 건강기능식품으로 인정되는 제형이면 제한 없이 제조될 수 있다. 본 발명의 건강기능식품 조성물은 일반 약품과는 달리 식품을 원료로 하여 약품의 장기 복용 시 발생할 수 있는 부작용 등이 없는 장점이 있고, 휴대성이 뛰어나, 피부 미백 효과를 증진시키기 위한 보조제로 섭취가 가능하다.In the present invention, the term "health functional food" refers to a food prepared and processed in the form of tablets, capsules, powders, granules, liquids and pills using raw materials or ingredients having useful functions for the human body. Here, 'functional' means to obtain a useful effect for health purposes such as nutrient control or physiological action on the structure and function of the human body. The health functional food of the present invention can be prepared by a method commonly used in the art, and the preparation can be prepared by adding raw materials and ingredients commonly added in the art. In addition, the formulation of the health functional food may also be prepared without limitation as long as the formulation is recognized as a health functional food. The health functional food composition of the present invention has the advantage that there is no side effect that can occur when taking a long-term use of the drug, unlike foods as a raw material, excellent portability, intake as an adjuvant to enhance the skin whitening effect It is possible.
본 발명의 건강기능식품 조성물은 정제, 과립, 분말, 캅셀, 액상의 용액 및 환으로 이루어진 군으로부터 선택된 어느 하나의 제형으로 제조된 것일 수 있다.The dietary supplement composition of the present invention may be prepared in any one formulation selected from the group consisting of tablets, granules, powders, capsules, liquid solutions and rings.
본 발명에 따른 건강기능식품 조성물은 옥타데센(octadecene) 또는 이의 염을 유효성분으로 포함시켜 분말제, 액제, 정제, 연질캅셀제, 과립제, 티백차, 인스턴트 차 또는 드링크제 등의 형태로 제형화될 수 있다. 유효성분으로서의 옥타데센 또는 이의 염의 함량은 그 사용 목적(예방 또는 개선용)에 따라 적합하게 결정될 수 있다. 일반적으로, 건강기능식품 조성물 중에 포함되는 상기 유효성분(옥타데센 또는 이의 염)의 양은 전체 식품 중량의 0.1 내지 20 중량%로 가할 수 있다. 그러나 건강 및 위생을 목적으로 하거나 또는 건강 조절을 목적으로 하는 장기간의 섭취의 경우에는 상기 양은 상기 범위 이하일 수 있다. 또한, 본 발명에 따른 건강기능식품 조성물은 상기 유효성분 이외에 본 발명이 목적으로 하는 주효과를 손상시키지 않는 범위 내에서 바람직하게는 주효과에 상승효과를 줄 수 있는 다른 성분 예를 들면, 비타민 C와 같은 미백 개선용 화합물 또는 녹차 추출물, 닥나무 추출물, 감초추출물, 상백피 추출물, 빈랑자 추출물, 황금 추출물, 산삼 추출물 등의 천연물을 함유하는 것도 무방하다.Health functional food composition according to the present invention may be formulated in the form of powder, liquid, tablets, soft capsules, granules, tea bags, instant tea or drink by including octadecene or salts thereof as an active ingredient. have. The content of octadecene or its salt as an active ingredient can be suitably determined according to the purpose of use (prevention or improvement). In general, the amount of the active ingredient (octadecene or salt thereof) included in the nutraceutical composition may be added at 0.1 to 20% by weight of the total food weight. However, for long term intakes for health and hygiene purposes or for health control purposes, the amount may be below this range. In addition, the health functional food composition according to the present invention, in addition to the active ingredient within the range that does not impair the main effect of the present invention, for example, other ingredients that can give a synergistic effect to the main effect, for example vitamin C It may also contain natural compounds such as whitening improvement compounds or green tea extracts, mulberry extract, licorice extract, lettuce extract, betel nut extract, golden extract, wild ginseng extract.
상기와 같은 형태로 제형화된 건강기능식품 조성물은 식품에 그대로 첨가하거나 다른 식품 또는 식품 성분과 함께 사용될 수 있고, 통상적인 방법에 따라 적절하게 사용될 수 있다. 식품의 예로는 드링크제, 육류, 소시지, 빵, 비스킷, 떡, 초콜릿, 캔디류, 스낵류, 과자류, 피자, 라면, 기타 면류, 껌류, 아이스크림류를 포함한 낙농제품, 각종 스프, 음료수, 알코올 음료 및 비타민 복합제, 유제품 및 유가공 제품 등이 있으며, 통상적인 의미에서의 건강기능식품은 모두 포함한다.The dietary supplement composition formulated in the form as described above may be added to the food as it is, or used with other foods or food ingredients, and may be appropriately used according to conventional methods. Examples of foods include drinks, meat, sausages, breads, biscuits, rice cakes, chocolate, candy, snacks, confectionery, pizza, ramen, dairy products including other noodles, gums, ice creams, various soups, beverages, alcoholic beverages and vitamin complexes. , Dairy products and dairy products, and all functional foods in the usual sense.
본 발명의 건강기능식품 조성물이 드링크제인 경우는 지시된 비율로 필수성분으로서 옥타데센 또는 이의 염을 함유하며, 그 밖의 드링크제 제조를 목적으로 사용되는 다른 성분에는 특별한 제한이 없으며 통상의 음료와 같이 여러 가지 향미제 또는 천연 탄수화물 등을 추가 성분으로서 함유할 수 있다. 상기한 천연 탄수화물의 예는 모노사카라이드, 예를 들어, 포도당, 과당 등; 디사카라이드, 예를 들어 말토스, 슈크로스 등; 및 폴리사카라이드, 예를 들어 덱스트린, 시클로덱스트린 등과 같은 통상적인 당, 및 자일리톨, 소르비톨, 에리트리톨 등의 당알콜이다. 상술한 것 이외의 향미제로서 천연 향미제 및 합성 향미제 등을 사용할 수 있다. 상기 천연 탄수화물의 비율은 본 발명의 조성물 100 ㎖당 일반적으로 약 1 내지 20 g, 바람직하게는 약 5 내지 12 g이다.When the health functional food composition of the present invention is a drink, it contains an octadecene or a salt thereof as an essential ingredient in the indicated ratio, and there are no particular limitations on other ingredients used for the purpose of preparing other drink agents, Eggplant flavor or natural carbohydrate and the like may be included as additional ingredients. Examples of such natural carbohydrates include monosaccharides such as glucose, fructose and the like; Disaccharides such as maltose, sucrose and the like; And conventional sugars such as polysaccharides such as dextrin, cyclodextrin, and sugar alcohols such as xylitol, sorbitol, and erythritol. As a flavoring agent other than the above-mentioned, a natural flavoring agent, a synthetic flavoring agent, etc. can be used. The proportion of such natural carbohydrates is generally about 1-20 g, preferably about 5-12 g per 100 ml of the composition of the present invention.
또한 본 발명의 건강기능식품 조성물은 여러 가지 영양제, 비타민, 광물(전해질), 합성 풍미제 및 천연 풍미제 등의 풍미제, 착색제 및 중진제(치즈, 초콜릿 등), 펙트산 및 그의 염, 알긴산 및 그의 염, 유기산, 보호성 콜로이드 증점제, pH 조절제, 안정화제, 방부제, 글리세린, 알코올, 탄산음료에 사용되는 탄산화제 등을 함유할 수 있다. 그 밖에도 본 발명의 본 발명의 식품 조성물은 천연 과일 쥬스 및 과일 쥬스 음료 및 야채 음료의 제조를 위한 과육을 함유할 수 있다. 이러한 성분은 독립적으로 또는 조합하여 사용할 수 있다. 이러한 첨가제의 비율은 그렇게 중요하진 않지만 본 발명의 유효성분(옥타데센 또는 이의 염) 100 중량부 당 0.1 내지 약 20 중량부의 범위에서 선택되는 것이 일반적이다.In addition, the health functional food composition of the present invention is a variety of nutrients, vitamins, minerals (electrolytes), flavors such as synthetic and natural flavors, coloring and neutralizing agents (such as cheese, chocolate), pectic acid and salts thereof, alginic acid And salts thereof, organic acids, protective colloid thickeners, pH adjusters, stabilizers, preservatives, glycerin, alcohols, carbonation agents used in carbonated drinks, and the like. In addition, the food composition of the present invention may contain a pulp for producing natural fruit juice and fruit juice beverage and vegetable beverage. These components can be used independently or in combination. The proportion of such additives is not so critical but is generally selected in the range of 0.1 to about 20 parts by weight per 100 parts by weight of the active ingredient (octadecene or salt thereof) of the present invention.
또한 본 발명은, 옥타데센(octadecene) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 색소 침착의 예방 또는 치료용 약학적 조성물을 제공한다. In another aspect, the present invention provides a pharmaceutical composition for the prevention or treatment of skin pigmentation, including octadecene or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명의 옥타데센 또는 이의 염의 함량은 조성물의 총 중량을 기준으로 각각 0.0001 내지 20 중량% 인 것이 바람직하다. 20 중량%를 초과하는 경우에는 효과의 변화가 미미하거나 기존에 알려진 독성을 나타낼 수 있고, 0.0001% 미만의 경우에는 그 작용효과가 미미하다.The content of octadecene or salt thereof of the present invention is preferably 0.0001 to 20% by weight, respectively, based on the total weight of the composition. If it exceeds 20% by weight, the change in effect may be insignificant or may have known toxicity, and if it is less than 0.0001%, the effect may be insignificant.
본 발명의 옥타데센(octadecene) 또는 이의 약학적으로 허용 가능한 염을 의약품으로 사용하는 경우, 추가로 동일 또는 유사한 기능을 나타내는 유효성분을 1종 이상 함유할 수 있다. 예컨대, 공지의 미백 성분을 포함할 수 있을 것이다. 추가적인 미백 성분을 포함하게 되면 본 발명의 조성물의 피부 미백 효과는 더욱 증진될 수 있다. 상기 성분 추가 시에는 복합 사용에 따른 피부 안전성, 제형화의 용이성, 유효성분들의 안정성을 고려할 수 있다. 본 발명의 일실시예에서, 상기 의약품 조성물은 당업계에 공지된 미백 성분으로서, 비타민 C 등을 추가로 포함할 수 있다. 추가의 미백 개선 성분은 전체 조성물 중량에 대하여 0.0001 내지 10 중량%로 포함될 수 있을 것이며, 상기 함량 범위는 티로시나아제의 활성 억제 효과, 피부 안전성, 상기 화학식 1의 화합물의 제형화 시의 용이성 등의 요건에 따라 조절될 수 있을 것이다.When octadecene or a pharmaceutically acceptable salt thereof of the present invention is used as a medicine, it may further contain one or more active ingredients exhibiting the same or similar functions. For example, known whitening ingredients may be included. Inclusion of additional whitening ingredients can further enhance the skin lightening effect of the compositions of the present invention. When the ingredient is added, skin safety, ease of formulation, and stability of the active ingredients may be considered. In one embodiment of the present invention, the pharmaceutical composition may further include vitamin C and the like as a whitening component known in the art. Additional whitening improving ingredients may be included in an amount of 0.0001 to 10% by weight based on the total weight of the composition, the content range of the activity inhibitory effect of tyrosinase, skin safety, ease of formulating the compound of Formula 1 It may be adjusted according to the requirements.
또한, 본 발명의 피부 색소 침착의 예방 또는 치료용 약학적 조성물은 약학적으로 허용 가능한 담체를 더 포함할 수 있다.In addition, the pharmaceutical composition for preventing or treating skin pigmentation of the present invention may further include a pharmaceutically acceptable carrier.
약학적으로 허용되는 담체는 완충액, 주사용 멸균수, 일반 식염수 또는 인산염 완충 식염수, 슈크로스, 히스티딘, 염 및 폴리솔베이트 등과 같은 여러 성분을 함유할 수 있다.Pharmaceutically acceptable carriers may contain various components such as buffers, sterile water for injection, general saline or phosphate buffered saline, sucrose, histidine, salts, polysorbates and the like.
본 발명의 약학적 조성물은 경구 또는 비경구로 투여할 수 있으며, 일반 의약품 제제의 형태, 예를 들어, 임상투여 시 경구 및 비경구의 여러 가지 제형으로 투여될 수 있는데, 제제화할 경우에는 보통 사용하는 충진제, 증량제, 결합제, 습윤제, 붕해제, 계면활성제 등의 희석제 또는 부형제를 사용하여 조제될 수 있다.The pharmaceutical composition of the present invention may be administered orally or parenterally, and may be administered in the form of a general pharmaceutical preparation, for example, in various dosage forms, orally and parenterally, during clinical administration. , Diluents or excipients such as extenders, binders, wetting agents, disintegrants, surfactants and the like.
경구투여를 위한 고형제제에는 정제, 환제, 산제, 과립제, 캡슐제 등이 포함되며, 이러한 고형제제는 본 발명의 약학적 조성물에 적어도 하나 이상의 부형제 예를 들면, 전분, 칼슘카보네이트(Calcium carbonate), 수크로스(Sucrose) 또는 락토오스(Lactose), 젤라틴 등을 섞어 조제될 수 있다.Solid preparations for oral administration include tablets, pills, powders, granules, capsules, and the like, and the solid preparations include at least one excipient such as starch, calcium carbonate, It may be prepared by mixing sucrose or lactose, gelatin and the like.
단순한 부형제 이외에 마그네슘 스티레이트 탈크 같은 윤활제들도 사용된다. 경구를 위한 액상 제제로는 현탁제, 내용액제, 유제, 시럽제 등이 해당되는데 흔히 사용되는 단순희석제인 물, 리퀴드 파라핀 이외에 여러 가지 부형제, 예를 들면 습윤제, 감미제, 방향제, 보존제 등이 포함될 수 있다.In addition to simple excipients, lubricants such as magnesium styrate talc are also used. Oral liquid preparations include suspensions, solvents, emulsions, and syrups, and may include various excipients, such as wetting agents, sweeteners, fragrances, and preservatives, in addition to commonly used simple diluents such as water and liquid paraffin. .
비경구 투여를 위한 제제에는 멸균된 수용액, 비수성용제, 현탁제, 유제, 동결건조제제, 좌제가 포함된다. 비수성용제, 현탁용제로는 프로필렌 글리콜(Propylene glycol), 폴리에틸렌 글리콜, 올리브 오일과 같은 식물성 기름, 에틸올레이트와 같은 주사 가능한 에스테르 등이 사용될 수 있다. 좌제의 기제로는 위텝솔(witepsol), 마크로골, 트윈(tween) 61, 카카오지, 라우린지, 글리세로제라틴 등이 사용될 수 있다.Formulations for parenteral administration include sterile aqueous solutions, non-aqueous solvents, suspensions, emulsions, lyophilized preparations, suppositories. As the non-aqueous solvent and the suspension solvent, propylene glycol, polyethylene glycol, vegetable oil such as olive oil, injectable ester such as ethyl oleate, and the like can be used. As the base of the suppository, witepsol, macrogol, tween 61, cacao butter, laurin butter, glycerogelatin and the like can be used.
본 발명의 약학적 조성물은 유효량의 옥타데센(octadecene) 또는 이의 약학적으로 허용 가능한 염을 포함할 때 바람직한 피부 색소 침착의 예방 또는 치료를 제공할 수 있다. 본 발명에 있어서, '유효량'이라 함은 피부 색소 침착이 생성되는 것을 억제 또는 저해하거나, 이미 생성된 색소를 완화시킬 수 있는 화합물의 양을 의미한다. 본 발명의 조성물에 포함되는 옥타데센(octadecene) 또는 이의 약학적으로 허용 가능한 염의 유효량은 조성물이 제품화되는 형태, 상기 화합물이 피부에 적용되는 방법 및 피부에 머무르는 시간 등에 따라 달라질 수 있다. 예컨대, 상기 조성물이 피부의 색소 침착 등에 따른 피부과적 치료를 위한 의약품으로 제품화되는 경우에는 일상적으로 피부에 적용하게 되는 화장품으로 제품화되는 경우에 비해 높은 농도로 옥타데센(octadecene) 또는 이의 약학적으로 허용 가능한 염을 포함할 수 있을 것이다.The pharmaceutical compositions of the present invention may provide for the prevention or treatment of desirable skin pigmentation when it contains an effective amount of octadecene or a pharmaceutically acceptable salt thereof. In the present invention, the term 'effective amount' means an amount of a compound capable of inhibiting or inhibiting the generation of skin pigmentation or alleviating a pigment already produced. The effective amount of octadecene or a pharmaceutically acceptable salt thereof included in the composition of the present invention may vary depending on the form in which the composition is commercialized, the method by which the compound is applied to the skin, the time it stays on the skin, and the like. For example, when the composition is commercialized as a medicine for dermatological treatment due to pigmentation of the skin, octadecene or a pharmaceutically acceptable thereof at a higher concentration than when commercialized as a cosmetic product that is applied to the skin on a daily basis. Possible salts may be included.
또한 본 발명은, 옥타데센(octadecene) 또는 이의 약학적으로 허용 가능한 염을 유효성분으로 포함하는 피부 색소 침착의 예방 또는 개선용 의약외품 조성물을 제공한다.The present invention also provides a quasi-drug composition for the prevention or improvement of skin pigmentation comprising octadecene or a pharmaceutically acceptable salt thereof as an active ingredient.
본 발명에서 사용되는 용어 "의약외품"은 사람이나 동물의 질병을 진단, 치료, 개선, 경감, 처치 또는 예방할 목적으로 사용되는 물품들 중 의약품보다 작용이 경미한 물품들을 의미하는 것으로, 예를 들어 약사법에 따르면 의약외품이란 의약품의 용도로 사용되는 물품을 제외한 것으로, 사람ㆍ동물의 질병 치료나 예방에 쓰이는 제품, 인체에 대한 작용이 경미하거나 직접 작용하지 않는 제품 등이 포함된다.The term "quasi drug" used in the present invention refers to articles that have a lesser action than medicines among articles used for the purpose of diagnosing, treating, ameliorating, reducing, treating, or preventing a disease of a human or animal. According to the quasi-drug product, the product used for the purpose of medicine is excluded, and it is used for the treatment or prevention of diseases of humans and animals, and the products that have little or no direct action on the human body.
본 발명의 의약외품 조성물은 피부 색소 침착의 예방 또는 개선을 목적으로 사용되는 것으로, 그 제형에 있어서 특별히 한정되는 바가 없으며, 예를 들면, 유연화장수, 영양화장수, 마사지크림, 영양크림, 팩, 마스크팩, 마스크시트, 젤 또는 피부 점착타입 화장료의 제형을 갖는 화장료 조성물일 수 있으며, 또한, 로션, 연고, 겔, 크림, 패취 또는 분무제와 같은 경피투여형 제형일 수 있다.The quasi-drug composition of the present invention is used for the purpose of preventing or improving skin pigmentation, and is not particularly limited in the formulation thereof. For example, supple cosmetics, nourishing cosmetics, massage creams, nourishing creams, packs, and mask packs. It may be a cosmetic composition having a formulation of a mask sheet, a gel or a skin adhesive cosmetic, and may also be a transdermal formulation such as a lotion, ointment, gel, cream, patch or spray.
또한, 각 제형에 있어서 의약외품 조성물은 다른 성분들을 기타 의약외품의 제형 또는 사용목적 등에 따라 임의로 선정하여 배합할 수 있다. 유효 성분의 혼합양은 사용 목적(억제 또는 완화)에 따라 적합하게 결정될 수 있다. 예를 들어, 점증제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 및 담체 등을 포함할 수 있다.In addition, in each formulation, the quasi-drug composition may be optionally selected and blended with other ingredients according to the formulation or purpose of use of the other quasi-drug. The mixed amount of the active ingredient can be suitably determined according to the purpose of use (inhibition or relaxation). For example, thickeners, stabilizers, solubilizers, conventional adjuvants such as vitamins, pigments and flavors, and carriers and the like.
본 발명의 옥타데센 또는 이의 염의 함량은 의약외품 조성물의 총 중량을 기준으로 각각 0.0001 내지 20 중량% 인 것이 바람직하다. 20 중량%를 초과하는 경우에는 조성물 제조 시 색상 및 안정성이 떨어질 수 있고, 0.0001% 미만의 경우에는 그 작용효과가 미미하다.The content of the octadecene or salt thereof of the present invention is preferably 0.0001 to 20% by weight, respectively, based on the total weight of the quasi-drug composition. If the content exceeds 20% by weight, the color and stability of the composition may be degraded. If the content is less than 0.0001%, the effect is minimal.
또한, 각 제형의 의약외품 조성물에 있어서, 상기한 필수 성분 이외의 다른 성분들은 제형 또는 사용목적 등에 따라 당업자가 어려움 없이 적의 선정하여 배합할 수 있다.In addition, in the quasi-drug composition of each formulation, other components than the essential components described above can be appropriately selected and blended by those skilled in the art without difficulty according to the formulation or purpose of use.
이하, 실시예를 통하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail with reference to Examples. These examples are only for illustrating the present invention, and it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as being limited by these examples.
실시예: B6F10 멜라닌세포(B6F10 melanocyte)를 이용한 옥타데센의 멜라닌 생성 억제 효능 평가Example: Evaluation of melanogenesis inhibitory effect of octadecene using B6F10 melanocytes
1-1. 실험방법1-1. Experiment method
1) 실험재료 및 세포배양1) Experimental material and cell culture
본 실험에서 사용된 α-MSH (alpha-melanocyte stimulating hormone) 및 옥타데센(Octadecene)은 모두 Sigma Aldrich(St Louis, MO, USA) 사에서 구입하였다. B16F10 멜라닌세포(B16F10 melanocyte)는 ATCC사(Manassas, VA, USA)에서 구입하여 사용하였으며, 구입한 세포는 FBS(fetal bovin serum)가 포함된 DMEM(Dulbecco's Modified Eagle's Media) 배지를 이용하여 37℃, 5% CO2 인큐베이터에서 배양하였다.Α-MSH (alpha-melanocyte stimulating hormone) and octadecene (Octadecene) used in this experiment were all purchased from Sigma Aldrich (St Louis, MO, USA). B16F10 melanocytes (B16F10 melanocyte) was purchased from ATCC (Manassas, VA, USA) and used, and the purchased cells were 37 ℃, using Dulbecco's Modified Eagle's Media (DMEM) medium containing FBS (fetal bovin serum) Incubated in a 5% CO 2 incubator.
2) 세포 내 멜라닌 생성량 측정2) Measurement of melanin production in cells
B6F10 멜라닌세포를 10% FBS가 포함된 DMEM배지에서 37℃, 5% CO2 조건에서 배양 후 6 웰 플레이트에 1×105 cells/well로 분주하여 세포를 부착시켰다. 정상세포는 멜라닌 생성을 유도하는 α-MSH를 처리하지 않은 세포로, 대조세포는 α-MSH(100 nM)을 처리한 세포로 설정하였다. 상기 조건으로 배양한 세포에 α-MSH(100 nM)와 함께 옥타데센(100 μM)을 처리하고 48 시간 동안 배양하였다. B6F10 melanocytes were cultured in DMEM medium containing 10% FBS at 37 ° C. and 5% CO 2 , and then cultured into 6 well plates at 1 × 10 5 cells / well to attach cells. Normal cells were set to cells not treated with α-MSH that induces melanogenesis, and control cells were treated with cells treated with α-MSH (100 nM). Cells cultured under the above conditions were treated with octadecene (100 μM) together with α-MSH (100 nM) and incubated for 48 hours.
이후 PBS(phosphate buffered saline)로 2회 세척 후 세포를 회수하였다. 회수한 세포는 1,000 rpm으로 5 분간 원심분리 후 육안으로 펠릿(pellet) 색을 관찰하였다. 이후 세포 펠릿은 10% DMSO가 첨가된 1N NaOH 용액 200 μL을 넣어 용해시킨 다음 마이크로플레이트 리더(microplate reader)로 400 nm에서 흡광도를 측정하였다.After washing twice with PBS (phosphate buffered saline) cells were recovered. The recovered cells were centrifuged at 1,000 rpm for 5 minutes and visually observed pellet color. Cell pellets were then lysed with 200 μL of 1N NaOH solution added with 10% DMSO and then absorbance was measured at 400 nm with a microplate reader.
3) RNA 추출 및 PCR 분석3) RNA extraction and PCR analysis
총 RNA는 트리졸(Trizol)을 이용하여 세포에서 추출하였으며, 추출된 RNA 시료를 대상으로 dT 프라이머(oligo dT primer)와 역전사 효소(superscript reverse transcriptase, GIBCO BRL, Gaithersburg, MD, USA)를 이용하여 역전사(reverse transcription)를 수행하여 cDNA를 합성하였다. 역전사(reverse transcription)를 통해 얻은 cDNA를 주형(template)으로 하고 증폭하고자 하는 유전자 cDNA의 5'과 3'플랭킹 서열(flanking sequence)을 프라이머로 하며, iQ SYBR green supermix (Bio-Rad)와 CFX Connect™ Real-Time PCR Detection System (Bio-Rad)을 사용하여 정량적 PCR을 수행하였다. 이때 사용된 프라이머 서열(primer sequence)은 [표 1]에 나타내었다. Total RNA was extracted from cells using Trizol, and the extracted RNA samples were extracted using oligo dT primer and superscript reverse transcriptase (GIBCO BRL, Gaithersburg, MD, USA). Reverse transcription was performed to synthesize cDNA. The cDNA obtained through reverse transcription was used as a template and the 5 'and 3' flanking sequences of the gene cDNA to be amplified as primers, and iQ SYBR green supermix (Bio-Rad) and CFX. Quantitative PCR was performed using the Connect ™ Real-Time PCR Detection System (Bio-Rad). The primer sequence used at this time is shown in [Table 1].
(서열번호 1)CTCTGGGCTTAGCAGTAGGC
(SEQ ID NO 1)
(서열번호 2)GCAAGCTGTGGTAGTCGTCT
(SEQ ID NO: 2)
(microphthalmia transcription factor)MITF
(microphthalmia transcription factor)
(서열번호 3)AGCGTGTATTTTCCCCACAG
(SEQ ID NO: 3)
(서열번호 4)TAGCTCCTTAATGCGGTCGT
(SEQ ID NO: 4)
(서열번호 5)CAAAATGGTGAAGGTCGGTG
(SEQ ID NO: 5)
104
(서열번호 6)TTTGCCGTGAGTGGAGTCAT
(SEQ ID NO: 6)
1-2. 실험결과1-2. Experiment result
1) B6F10 멜라닌세포(B16F10 melanocyte)에서 옥타데센의 멜라닌 생성 억제 효과 1) Inhibitory effect of octadecene on melanogenesis in B6F10 melanocytes
멜라닌은 멜라닌 세포 내 세포 소기관인 멜라노좀에서 합성이 개시되며 자외선에 노출되면 멜라닌 세포가 활성화되면서 일련의 효소반응을 거쳐 생성된다. Melanin is synthesized in melanocytes, the organelles of melanocytes, and is produced through a series of enzymatic reactions when melanocytes are activated when exposed to ultraviolet rays.
B6F10 멜라닌세포의 펠릿(pellet) 색을 육안적으로 관찰한 결과, α-MSH를 처리한 대조세포의 펠릿은 α-MSH를 처리하지 않은 정상세포의 펠릿에 비해 검은색으로 변한 것을 확인하였다. α-MSH와 함께 옥타데센을 처리한 세포 펠릿의 색은 α-MSH만 처리한 대조세포에 비해 현저히 옅어진 것을 확인할 수 있었다(도 1). 이를 녹여서 색을 정량한 결과, α-MSH를 처리한 대조세포의 멜라닌 함량은 α-MSH를 처리하지 않은 정상세포에 비해 136% 유의적으로 증가하였다. 한편, α-MSH와 함께 옥타데센을 처리한 세포에서 멜라닌 함량은 대조세포에 비해 27% 유의적으로 감소한 것을 확인하였다(도 2). 따라서, 옥타데센의 멜라닌 생성 저해 효과가 우수함을 알 수 있다.As a result of visual observation of the pellet color of B6F10 melanocytes, it was confirmed that the pellets of the control cells treated with α-MSH turned black compared to the pellets of normal cells not treated with α-MSH. It was confirmed that the color of the cell pellet treated with octadecene with α-MSH was significantly lighter than control cells treated with α-MSH alone (FIG. 1). As a result of melting the color, the melanin content of control cells treated with α-MSH was increased by 136% compared with normal cells without treatment with α-MSH. On the other hand, melanin content in cells treated with octadecene with α-MSH was found to be significantly reduced by 27% compared to the control cells (Fig. 2). Thus, it can be seen that the octadecene melanin production inhibitory effect is excellent.
2) B6F10 멜라닌세포에서 유전자 발현변화를 통한 멜라닌 생성 억제 확인 2) Confirmation of inhibition of melanin production by changing gene expression in B6F10 melanocytes
티로시나아제는 멜라닌세포 내 멜라닌 합성의 초기단계에 작용하여 멜라닌 합성 속도를 조절하는 것으로 잘 알려져 있으며, MITF는 티로시나아제의 유전자 프로모터(gene promotor)에 존재하는 E-box (CATGTG)에 결합하여 효소 발현을 유도하는 것으로 알려져 있다.Tyrosinase is well known to regulate the rate of melanogenesis by acting at the initial stage of melanin synthesis in melanocytes, and MITF binds to the E-box (CATGTG) present in the tyrosinase gene promoter. It is known to induce enzyme expression.
옥타데센의 멜라닌 생성 억제효과가 티로시나아제와 같은 효소 발현 억제와 전사 인자(transcription factor)인 MITF 발현 조절과 관련되었는지 확인하고자 B6F10 멜라닌세포에서 PCR 분석을 수행하였다. 그 결과, 정상세포(basal)에 비해 α-MSH를 처리한 대조세포에서 MITF 및 티로시나아제의 발현이 유의적으로 증가한 것을 확인하였으며, α-MSH와 함께 옥타데센을 처리한 세포에서는 대조세포에 비해 MITF 및 티로시나아제의 발현이 각각 36%, 30% 유의적으로 감소한 것을 확인하였다(도 3). PCR analysis was performed on B6F10 melanocytes to determine whether the octadecene melanin production inhibitory effect was related to inhibition of enzyme expression such as tyrosinase and regulation of MITF expression, a transcription factor. As a result, it was confirmed that the expression of MITF and tyrosinase was significantly increased in the control cells treated with α-MSH compared to the basal cells, and in the control cells treated with octadecene with α-MSH. In comparison, it was confirmed that the expression of MITF and tyrosinase was significantly reduced by 36% and 30%, respectively (FIG. 3).
[제조예 1] 화장품의 제조Preparation Example 1 Preparation of Cosmetics
1-1. 유연 화장수의 제조1-1. Preparation of Flexible Lotion
하기 표 2의 조성으로, 옥타데센을 함유하는 유연 화장수를 제조하였다.To the composition of Table 2 below, a flexible lotion containing octadecene was prepared.
1-2. 영양 화장수의 제조1-2. Manufacture of nutritional lotion
하기 표 3의 조성으로, 옥타데센을 함유하는 영양 화장수를 제조하였다.In the composition of Table 3 below, a nourishing lotion containing octadecene was prepared.
1-3. 영양 크림의 제조1-3. Manufacture of nutritional cream
하기 표 4의 조성으로, 옥타데센을 함유하는 영양 크림을 제조하였다.In the composition of Table 4 below, a nourishing cream containing octadecene was prepared.
1-4. 팩의 제조1-4. Manufacture of pack
하기 표 5의 조성으로, 옥타데센을 함유하는 팩을 제조하였다.In the composition of Table 5 below, a pack containing octadecene was prepared.
1-5. 에센스의 제조1-5. Preparation of essence
하기 표 6의 조성으로, 옥타데센을 함유하는 에센스를 제조하였다.With the composition of Table 6 below, an essence containing octadecene was prepared.
[제조예 2] 건강기능식품의 제조Preparation Example 2 Preparation of Health Functional Food
2-1. 건강기능식품의 제조2-1. Manufacturing of dietary supplements
하기 표 7의 조성으로, 옥타데센을 함유하는 건강기능식품을 제조하였다.To the composition of Table 7, a dietary supplement containing octadecene was prepared.
상기 비타민 및 미네랄 혼합물의 조성비는 비교적 건강기능식품에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 그 배합비를 임의로 변형 실시하여도 무방하며, 통상의 건강기능식품 제조방법에 따라 상기의 성분을 혼합한 다음, 과립을 제조하고, 통상의 방법에 따라 건강기능식품 조성물 제조에 사용할 수 있다.The composition ratio of the vitamin and mineral mixtures is a relatively suitable composition for the health functional food in a preferred embodiment, but the composition ratio may be arbitrarily modified, mixing the above components in accordance with a conventional health functional food manufacturing method Next, the granules may be prepared and used for preparing the nutraceutical composition according to a conventional method.
2-2. 건강 음료의 제조2-2. Manufacture of healthy drinks
하기 표 8의 조성으로, 옥타데센을 함유하는 건강 음료를 제조하였다.With the composition of Table 8 below, a health beverage containing octadecene was prepared.
통상의 건강 음료 제조방법에 따라 상기의 성분을 혼합한 다음, 약 1시간 동안 85 에서 교반 가열한 후 만들어진 용액을 여과하여 멸균된 21 용기에 취득하여 밀봉 멸균한 뒤 냉장 보관한 다음 볼 발명의 건강 음료 조성물의 제조에 사용한다. 상기 조성비는 비교적 기호음료에 적합한 성분을 바람직한 실시예로 혼합 조성하였지만, 수요계층, 수요국가, 사용용도 등 지역적, 민족적 기호도에 따라서 그 배합비를 임의로 변형 실시하여도 무방하다.After mixing the above components according to the conventional method for preparing a healthy beverage, the solution prepared by stirring and heating at 85 for about 1 hour and then obtained in a sterile 21 container obtained by sealing sterilization and refrigerated and then refrigerated Used to prepare beverage compositions. Although the composition ratio is mixed with a relatively suitable component for a preferred beverage in a preferred embodiment, the compounding ratio may be arbitrarily modified according to regional and ethnic preferences such as demand hierarchy, demand country, and usage.
2-3. 정제의 제조2-3. Manufacture of tablets
하기 표 9의 조성으로, 통상의 정제 제조방법에 따라 타정하여 옥타데센을 함유하는 정제를 제조하였다.To the composition shown in Table 9, by tableting according to the conventional tablet manufacturing method to prepare a tablet containing octadecene.
2-4. 캡슐제의 제조2-4. Preparation of Capsule
하기 표 10의 조성으로, 통상의 캡슐제 제조방법에 따라 젤라틴 캡슐에 충전하여 옥타데센을 함유하는 캡슐제를 제조하였다.To the composition of Table 10, according to the conventional capsule preparation method was filled in gelatin capsules to prepare a capsule containing octadecene.
2-5. 환의 제조2-5. Manufacture of rings
하기 표 11 조성으로, 통상의 환 제조 방법에 따라 1환 당 4 g이 되도록 환을 제조하였다.In the following Table 11, the ring was prepared to be 4 g per ring according to a conventional ring preparation method.
2-6. 과립의 제조2-6. Preparation of Granules
하기 표 12의 조성으로, 30% 에탄올 100 ㎎을 첨가하여 섭씨 60도에서 건조하여 과립을 형성한 후 포에 충진하여 과립을 제조하였다.To the composition of Table 12, 100 mg of 30% ethanol was added and dried at 60 degrees Celsius to form granules, which were then filled into a cloth to prepare granules.
[제조예 3][Production Example 3]
피부 외용 연고의 제조Preparation of skin ointments
하기 표 13의 조성으로, 옥타데센을 함유하는 피부 외용 연고를 제조하였다.To the composition of Table 13, an external skin ointment containing octadecene was prepared.
<110> Industry-Academic Cooperation Foundation, Yonsei University <120> COMPOSITION FOR SKIN WHITENING COMPRISING OCTADECENE OR ITS SALT AS ACTIVE INGREDIENTS <130> 1065212 <160> 6 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Tyrosinase_F primer <400> 1 ctctgggctt agcagtaggc 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Tyrosinase_R primer <400> 2 gcaagctgtg gtagtcgtct 20 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MITF_F primer <400> 3 agcgtgtatt ttccccacag 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MITF_R primer <400> 4 tagctcctta atgcggtcgt 20 <210> 5 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH_F primer <400> 5 caaaatggtg aaggtcggtg 20 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH_R primer <400> 6 tttgccgtga gtggagtcat 20 <110> Industry-Academic Cooperation Foundation, Yonsei University <120> COMPOSITION FOR SKIN WHITENING COMPRISING OCTADECENE OR ITS SALT AS ACTIVE INGREDIENTS <130> 1065212 <160> 6 <170> KoPatentIn 3.0 <210> 1 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Tyrosinase_F primer <400> 1 ctctgggctt agcagtaggc 20 <210> 2 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> Tyrosinase_R primer <400> 2 gcaagctgtg gtagtcgtct 20 <210> 3 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MITF_F primer <400> 3 agcgtgtatt ttccccacag 20 <210> 4 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> MITF_R primer <400> 4 tagctcctta atgcggtcgt 20 <210> 5 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH_F primer <400> 5 caaaatggtg aaggtcggtg 20 <210> 6 <211> 20 <212> DNA <213> Artificial Sequence <220> <223> GAPDH_R primer <400> 6 tttgccgtga gtggagtcat 20
Claims (7)
Octadecene (octadecene) or a cosmetic composition for skin whitening comprising a cosmetically acceptable salt thereof as an active ingredient.
상기 유효성분은 MITF(microphthalmia transcription factor) 또는 티로시나아제의 발현을 억제하는 것을 특징으로 하는 피부 미백용 화장료 조성물.
The method according to claim 1,
The active ingredient is a cosmetic composition for skin whitening, characterized in that it inhibits the expression of MITF (microphthalmia transcription factor) or tyrosinase.
상기 유효성분은 멜라닌 세포 자극 호르몬 (Melanocyte-Stimulating Hormone, α-MSH)에 의해 유도되는 멜라닌 생성을 억제하는 것을 특징으로 하는 화장료 조성물.
The method according to claim 1,
The active ingredient is a cosmetic composition, characterized in that to inhibit the production of melanin induced by melanocyte-stimulating hormone (Melanocyte-Stimulating Hormone, α-MSH).
상기 약학적 조성물은 비경구 투여용인 것을 특징으로 하는 피부 색소 침착의 예방 또는 치료용 약학적 조성물.
As a pharmaceutical composition for the prevention or treatment of skin pigmentation containing octadecene or a pharmaceutically acceptable salt thereof as an active ingredient,
The pharmaceutical composition for the prevention or treatment of skin pigmentation, characterized in that for parenteral administration.
상기 의약외품 조성물은 비경구 투여용인 것을 특징으로 하는 피부 색소 침착의 예방 또는 개선용 의약외품 조성물.As quasi-drug composition for the prevention or improvement of skin pigmentation containing octadecene or a pharmaceutically acceptable salt thereof as an active ingredient,
The quasi-drug composition is a parenteral composition for the prevention or improvement of skin pigmentation, characterized in that for parenteral administration.
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190071588A KR102076932B1 (en) | 2019-06-17 | 2019-06-17 | Composition for skin whitening comprising octadecene or its salt as active ingredients |
PCT/KR2020/007780 WO2020256381A1 (en) | 2019-06-17 | 2020-06-16 | Skin whitening composition comprising octadecene or salt thereof as active ingredient |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
KR1020190071588A KR102076932B1 (en) | 2019-06-17 | 2019-06-17 | Composition for skin whitening comprising octadecene or its salt as active ingredients |
Publications (1)
Publication Number | Publication Date |
---|---|
KR102076932B1 true KR102076932B1 (en) | 2020-02-12 |
Family
ID=69569821
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020190071588A KR102076932B1 (en) | 2019-06-17 | 2019-06-17 | Composition for skin whitening comprising octadecene or its salt as active ingredients |
Country Status (2)
Country | Link |
---|---|
KR (1) | KR102076932B1 (en) |
WO (1) | WO2020256381A1 (en) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020256381A1 (en) * | 2019-06-17 | 2020-12-24 | 연세대학교 산학협력단 | Skin whitening composition comprising octadecene or salt thereof as active ingredient |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522807A (en) * | 1982-01-25 | 1985-06-11 | Plough, Inc. | Substantive topical compositions |
JP2002249414A (en) * | 2001-02-16 | 2002-09-06 | L'oreal Sa | Cosmetic use of coplymer of vinylpyrrolidone and alkene for modifying an appearance of skin and/or semi-mucous membrane |
KR20050043781A (en) * | 2001-11-09 | 2005-05-11 | 바이어스도르프 악티엔게젤샤프트 | Cosmetic and/or dermatological preparation containing octadecene dicarboxylic acid and uv filtering substances |
JP2009040719A (en) * | 2007-08-09 | 2009-02-26 | Croda Japan Kk | Cosmetic composition |
KR20130125878A (en) * | 2012-05-10 | 2013-11-20 | (주) 닥터코스텍 | Cosmetic composition for whitening of the skin comprising hydroxamic acid derivatives |
KR20180117252A (en) | 2017-04-18 | 2018-10-29 | 한국 한의학 연구원 | A skin-whitening composition comprising spinosin |
Family Cites Families (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR102076932B1 (en) * | 2019-06-17 | 2020-02-12 | 연세대학교 산학협력단 | Composition for skin whitening comprising octadecene or its salt as active ingredients |
-
2019
- 2019-06-17 KR KR1020190071588A patent/KR102076932B1/en active IP Right Grant
-
2020
- 2020-06-16 WO PCT/KR2020/007780 patent/WO2020256381A1/en active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4522807A (en) * | 1982-01-25 | 1985-06-11 | Plough, Inc. | Substantive topical compositions |
US4522807B1 (en) * | 1982-01-25 | 1996-01-30 | Plough | Substantive topical compositions |
JP2002249414A (en) * | 2001-02-16 | 2002-09-06 | L'oreal Sa | Cosmetic use of coplymer of vinylpyrrolidone and alkene for modifying an appearance of skin and/or semi-mucous membrane |
KR20050043781A (en) * | 2001-11-09 | 2005-05-11 | 바이어스도르프 악티엔게젤샤프트 | Cosmetic and/or dermatological preparation containing octadecene dicarboxylic acid and uv filtering substances |
JP2009040719A (en) * | 2007-08-09 | 2009-02-26 | Croda Japan Kk | Cosmetic composition |
KR20130125878A (en) * | 2012-05-10 | 2013-11-20 | (주) 닥터코스텍 | Cosmetic composition for whitening of the skin comprising hydroxamic acid derivatives |
KR20180117252A (en) | 2017-04-18 | 2018-10-29 | 한국 한의학 연구원 | A skin-whitening composition comprising spinosin |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020256381A1 (en) * | 2019-06-17 | 2020-12-24 | 연세대학교 산학협력단 | Skin whitening composition comprising octadecene or salt thereof as active ingredient |
Also Published As
Publication number | Publication date |
---|---|
WO2020256381A1 (en) | 2020-12-24 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101855095B1 (en) | Composition for enhancing whitening | |
US8969408B2 (en) | Use of lignan-type compounds or extract of nutmeg or aril of nutmeg comprising the same | |
KR20210108911A (en) | A composition for antioxidant or whitening compriging rosemary ionic liquid extract | |
US20090226555A1 (en) | Extract of actinidia arguta for preventing and treating baldness disorders and seborrheic skin disorders | |
KR102076932B1 (en) | Composition for skin whitening comprising octadecene or its salt as active ingredients | |
KR102076933B1 (en) | Composition for skin whitening comprising carvone or its salt as active ingredients | |
KR101188682B1 (en) | Composition for skin whitening comprising extracts of Veronica longiofolia L. | |
KR102089209B1 (en) | Composition for skin whitening comprising guaiacol, phytol and cavacrol as active ingredients | |
KR102094949B1 (en) | Whitening composition containing extract, fractions or compound derived from Raphanus sativus L. var niger | |
KR101768626B1 (en) | Skin whitening composition comprising an extract obtained from carthamus tinctorius l. | |
KR20200047422A (en) | Composition for relieving and protecting skin irritation from environmental pollutants comprising nutmeg extract and macelignan | |
JP2004091398A (en) | Composition for promoting proteasome activity | |
KR102201305B1 (en) | A composition for skin whitening comprising Cimicifuga dahurica extract or a fraction thereof | |
KR102012366B1 (en) | Composition for whitening comprising Withania somnifera callus extract | |
KR102224313B1 (en) | Composition for skin whitening comprising scutellaria alpina extract | |
EP3925603A1 (en) | Composition for allergy prevention, atopic dermatitis alleviation or skin regeneration, containing, as active ingredient, undecane or undecanal | |
KR101579500B1 (en) | Skin whitening composition comprising an extract obtained from roots of coix lachryma-jobi var. mayuen | |
KR101993575B1 (en) | Composition comprising tetradecane as active ingredients for improving skin wrinkle, skin moisturizing or skin elasticity | |
KR102212343B1 (en) | Composition for skin anti-aging or moisturization comprising extract of marian plum | |
EP2092837A1 (en) | Compositions for skin whitening comprising (2Z, 8Z) - matricaria acid methyl ester | |
KR101827374B1 (en) | Composition for treating, improving or preventing aging and aging-related diseases | |
KR101256222B1 (en) | Method for removing the pigment of Red beet extract using irradiation | |
KR102200013B1 (en) | Composition comprising artemisia umbelliformis extract | |
KR20150019678A (en) | Composition for skin whitening | |
KR102468186B1 (en) | Composition for Skin-lightening Using an Extract of Lotus corniculatus var. japonica |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
E701 | Decision to grant or registration of patent right | ||
GRNT | Written decision to grant |